<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12684739</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>07</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>02</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0033-3158</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>168</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Psychopharmacology</Title>
                <ISOAbbreviation>Psychopharmacology (Berl.)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>339-43</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase. This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout. Finally, we examined the low dose of 150 mg/kg (50 mg/kg per day) using a similar washout period.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schiffer</LastName>
                    <ForeName>Wynne K</ForeName>
                    <Initials>WK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, NY 11794, USA. wynne@bnl.gov</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marsteller</LastName>
                    <ForeName>Douglas</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dewey</LastName>
                    <ForeName>Stephen L</ForeName>
                    <Initials>SL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DA15041</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F31-DA15874</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2003</Year>
                <Month>04</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Psychopharmacology (Berl)</MedlineTA>
            <NlmUniqueID>7608025</NlmUniqueID>
            <ISSNLinking>0033-3158</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.6.1.19</RegistryNumber>
                <NameOfSubstance UI="D000612">4-Aminobutyrate Transaminase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GR120KRT6K</RegistryNumber>
                <NameOfSubstance UI="D020888">Vigabatrin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VTD58H1Z2X</RegistryNumber>
                <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000612">4-Aminobutyrate Transaminase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017551">Microdialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009714">Nucleus Accumbens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020888">Vigabatrin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2002</Year>
                <Month>Nov</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2003</Year>
                <Month>Feb</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2003</Year>
                <Month>Apr</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12684739</ArticleId>
            <ArticleId IdType="doi">10.1007/s00213-003-1446-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21916510</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>10</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>01</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-4804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>54</Volume>
                    <Issue>20</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Oct</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal chemistry</Title>
                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>7299-317</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/jm200866y</ELocationID>
            <Abstract>
                <AbstractText>New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aimed at reducing serum protein binding led to the identification of several compounds that showed not only excellent affinities for the receptor (41 compounds with K(i) &lt; 10 nM) but also excellent potencies in a human whole blood assay (IC(50) &lt; 100 nM; PGD2-induced eosinophil shape change). Additional optimization of the PK characteristics led to the identification of several compounds suitable for in vivo testing. Of these, 19k and 19s were tested in two different pharmacological models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Crosignani</LastName>
                    <ForeName>Stefano</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland. stefano.crosignani@merckserono.net</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prêtre</LastName>
                    <ForeName>Adeline</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jorand-Lebrun</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fraboulet</LastName>
                    <ForeName>Gaële</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seenisamy</LastName>
                    <ForeName>Jeyaprakashnarayanan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Augustine</LastName>
                    <ForeName>John Kallikat</ForeName>
                    <Initials>JK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Missotten</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Humbert</LastName>
                    <ForeName>Yves</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cleva</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abla</LastName>
                    <ForeName>Nada</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daff</LastName>
                    <ForeName>Hamina</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schott</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schneider</LastName>
                    <ForeName>Manfred</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burgat-Charvillon</LastName>
                    <ForeName>Fabienne</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rivron</LastName>
                    <ForeName>Delphine</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamernig</LastName>
                    <ForeName>Ingrid</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arrighi</LastName>
                    <ForeName>Jean-François</ForeName>
                    <Initials>JF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaudet</LastName>
                    <ForeName>Marilène</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zimmerli</LastName>
                    <ForeName>Simone C</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Juillard</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnson</LastName>
                    <ForeName>Zoe</ForeName>
                    <Initials>Z</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Chem</MedlineTA>
            <NlmUniqueID>9716531</NlmUniqueID>
            <ISSNLinking>0022-2623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C568958">(4-chloro-2-((2-fluoro-5-(propylsulfonyl)phenyl)ethynyl)phenoxy)acetic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C568957">(4-chloro-2-((2-methyl-5-(propylsulfonyl)phenyl)ethynyl)phenoxy)acetic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000480">Alkynes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018926">Anti-Allergic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010642">Phenoxyacetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011982">Receptors, Prostaglandin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013450">Sulfones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C036293">prostaglandin D2 receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9006-59-1</RegistryNumber>
                <NameOfSubstance UI="D010047">Ovalbumin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000085">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000480">Alkynes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018926">Anti-Allergic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001667">Binding, Competitive</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001798">Blood Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018938">Caco-2 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002463">Cell Membrane Permeability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048430">Cell Shape</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002634">Chemotaxis, Leukocyte</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003877">Dermatitis, Contact</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004804">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008862">Microsomes, Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010047">Ovalbumin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010642">Phenoxyacetates</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011657">Pulmonary Eosinophilia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011869">Radioligand Assay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011971">Receptors, Immunologic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011982">Receptors, Prostaglandin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013450">Sulfones</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm200866y</ArticleId>
            <ArticleId IdType="pubmed">21916510</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15003088</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>03</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>04</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0160-6689</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>65</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of clinical psychiatry</Title>
                <ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A case report of mania related to discontinuation of bupropion therapy for smoking cessation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>277</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Michael</LastName>
                    <ForeName>Nikolaus</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Erfurth</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bergant</LastName>
                    <ForeName>Volker</ForeName>
                    <Initials>V</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Clin Psychiatry</MedlineTA>
            <NlmUniqueID>7801243</NlmUniqueID>
            <ISSNLinking>0160-6689</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>01ZG3TPX31</RegistryNumber>
                <NameOfSubstance UI="D016642">Bupropion</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016642">Bupropion</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003702">Delusions</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D016540">Smoking Cessation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>4</Month>
                <Day>20</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15003088</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19116715</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0843</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer chemotherapy and pharmacology</Title>
                <ISOAbbreviation>Cancer Chemother. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>177-81</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00280-008-0900-x</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of this report is to describe the management and outcome of an unusual complication of a commonly used chemotherapeutic agent. Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective report of the first case of gemcitabine-related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented. The hematologic response parameters and clinical outcomes to each of the therapies given are described.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Chemotherapy-induced HUS was aggressively treated with plasmapheresis, high-dose steroids, vincristine and rituximab. Platelet recovery and clinical improvement coincided with administration of rituximab. In addition, aggressive supportive measures to manage renal failure (hemodialysis) and labile hypertension, allowed this patient to have an extended survival as a result of successful therapy for this complication despite an underlying rapidly fatal malignancy.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This case highlights the importance of timely application of aggressive measures even in patients with known diagnosis of a fatal malignancy as these interventions can prolong life and be of palliative benefit.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bharthuar</LastName>
                    <ForeName>Anubha</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Egloff</LastName>
                    <ForeName>Lori</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Becker</LastName>
                    <ForeName>Joanne</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>George</LastName>
                    <ForeName>Marina</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lohr</LastName>
                    <ForeName>James W</ForeName>
                    <Initials>JW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deeb</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iyer</LastName>
                    <ForeName>Renuka V</ForeName>
                    <Initials>RV</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cancer Chemother Pharmacol</MedlineTA>
            <NlmUniqueID>7806519</NlmUniqueID>
            <ISSNLinking>0344-5704</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C092560">rituximab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0W860991D6</RegistryNumber>
                <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>57-22-7</RegistryNumber>
                <NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B76N6SBZ8R</RegistryNumber>
                <NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058846">Antibodies, Monoclonal, Murine-Derived</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006463">Hemolytic-Uremic Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010956">Plasmapheresis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-008-0900-x</ArticleId>
            <ArticleId IdType="pubmed">19116715</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15918587</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>05</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>07</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0031-7144</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>60</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Die Pharmazie</Title>
                <ISOAbbreviation>Pharmazie</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clozapine prevents apoptosis and enhances receptor-dependent respiratory burst in human neutrophils.</ArticleTitle>
            <Pagination>
                <MedlinePgn>364-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The present study was undertaken to determine if the antipsychotic drug clozapine (CLZ) in the concentration range 2-50 microM can rescue polymorphonuclear cells (PMNs) from undergoing apoptosis. Our results indicate that 20 microM CLZ can rescue PMNs both from UVB-accelerated (28.0% vs. 45.9% for control without CLZ; P &lt; 0.05) and from spontaneous (35.8% vs. 57.6%; P &lt; 0.05) apoptosis whereas 50 microM CLZ could rescue PMNs from spontaneous (34.3% vs. 57.6%; P &lt; 0.05) apoptosis only. Furthermore, since apoptosis has been reported to involve the impairment of PMN function, we evaluated the effects of CLZ on respiratory burst in UVB-irradiated and in unirradiated PMNs. When 20 or 50 microM CLZ-pretreated PMNs were aged in a culture during 4 h, the luminol-dependent chemiluminescence (CL) response was 3-fold (P &lt; 0.01) and 2.5-fold (P &lt; 0.05) increased, respectively, by subsequent exposure to serum opsonized zymosan (OZ). When 50 microM-pretreated PMNs were either UVB-irradiated or unirradiated, the CL response was 2.6-fold (P &lt; 0.05) and 3.3-fold (P &lt; 0.05) increased, respectively, after subsequent exposure to formyl-methionyl-leucyl-phenylalanine (fMLP). In contrast, the degree of enhancement was negligible upon subsequent exposure to ionomycin or phorbol myristate acetate (PMA). When incubation times were extended up to 22 h, the CL response induced by OZ in 20 microM CLZ-treated PMNs had a 4.9-fold increase (P &lt; 0.001). This priming effect could be reverted when 20 microM CLZ-treated PMNs (aged 4 h in culture) were coincubated for 5 min with the protein tyrosine kinase inhibitor genistein as well as with the phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin. These findings suggest that CLZ primes respiratory burst and prevents PMN apoptosis as a consequence of tyrosine phosphorylation- and PI3-K activation-dependent signal transduction pathways.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vargas</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratorio de Fotoquímica, Centro de Química, Instituto Venezolano de Investigaciones Científicas I.V.I.C., Caracas. fvargas@ivic.ve</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rivas</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perdomo</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rivas</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ojeda</LastName>
                    <ForeName>L E</ForeName>
                    <Initials>LE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Velásquez</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Correia</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernández</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fraile</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Pharmazie</MedlineTA>
            <NlmUniqueID>9800766</NlmUniqueID>
            <ISSNLinking>0031-7144</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006131">Growth Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>19545-26-7</RegistryNumber>
                <NameOfSubstance UI="C009687">wortmannin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9010-72-4</RegistryNumber>
                <NameOfSubstance UI="D015054">Zymosan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DH2M523P0H</RegistryNumber>
                <NameOfSubstance UI="D019833">Genistein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J60AR2IKIC</RegistryNumber>
                <NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000730">Androstadienes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053938">DNA Fragmentation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019833">Genistein</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006131">Growth Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008163">Luminescent Measurements</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009504">Neutrophils</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016897">Respiratory Burst</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014466">Ultraviolet Rays</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015054">Zymosan</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>5</Month>
                <Day>28</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>7</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>5</Month>
                <Day>28</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15918587</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21172400</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>03</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3185</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>280</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Feb</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology</Title>
                <ISOAbbreviation>Toxicology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Betulin and betulinic acid attenuate ethanol-induced liver stellate cell activation by inhibiting reactive oxygen species (ROS), cytokine (TNF-α, TGF-β) production and by influencing intracellular signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>152-63</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tox.2010.12.006</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Liver fibrosis has been reported to be inhibited in vivo by oleanolic and ursolic acids. However, the mechanisms of the action of those triterpenoids are poorly understood. In this study, we aimed to determine the antifibrotic potential of other triterpenes, betulin and betulinic acid, and to characterize their influence on the signal transduction pathways involved in ethanol-activated hepatic stellate cells (HSCs).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Investigated was the influence of preincubation of rat HSCs with betulin and betulinic acid, at non-toxic concentrations, on ethanol-induced toxicity, migration, and several markers of HSC activation such as smooth muscle α-actin (α-SMA) and procollagen I expression, release of reactive oxygen species (ROS) and cytokines: tumor necrosis factor-α (TNF-α) and tumor growth factor-β1 (TGF-β1), and production of metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). To assess the mechanism of the action of those triterpenes, intracellular signals such as nuclear factor-κB (NFκB), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38 MAPK) induced by ethanol were examined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In vitro, betulin, but not betulinic acid, protected HSCs against ethanol toxicity. However, both betulin and betulinic acid inhibited the production of ROS by HSCs treated with ethanol and inhibited their migration as well as ethanol-induced TNF-α, and TGF-β1, production. Betulin and betulinic acid down-regulated ethanol-induced production of TIMP-1 and TIMP-2. Betulin and betulinic acid, also decreased ethanol-induced activity of MMP-2. In ethanol-induced HSCs, betulin inhibited the activation of the p38 MAPK and the JNK transduction pathways, while betulinic acid inhibited the JNK transduction pathway only. They also significantly inhibited phosphorylation of IκB and Smad 3 and attenuated the activation of TGF-β1 and NFκB/IκB transduction signaling.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results indicated that betulin and betulinic acid inhibited ethanol-induced activation of HSCs on different levels, acting as antioxidants, inhibitors of cytokine production, and inhibitors of TGF-β, and NFκB/IκB transduction signaling. Betulin was also inhibitor of both JNK and p38 MAPK signal transduction, while betulinic acid inhibited only JNK. The remarkable inhibition of several markers of HCS activation makes triterpenes, especially betulin, promising agents for anti-fibrotic combination therapies.</AbstractText>
                <CopyrightInformation>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Szuster-Ciesielska</LastName>
                    <ForeName>Agnieszka</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology and Immunology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland. szustera@hektor.umcs.lublin.pl</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plewka</LastName>
                    <ForeName>Krzysztof</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daniluk</LastName>
                    <ForeName>Jadwiga</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kandefer-Szerszeń</LastName>
                    <ForeName>Martyna</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Toxicology</MedlineTA>
            <NlmUniqueID>0361055</NlmUniqueID>
            <ISSNLinking>0300-483X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3K9958V90M</RegistryNumber>
                <NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4G6A18707N</RegistryNumber>
                <NameOfSubstance UI="C002070">betulinic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6W70HN7X7O</RegistryNumber>
                <NameOfSubstance UI="C002503">betulin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000431">Ethanol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055166">Hepatic Stellate Cells</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007424">Intracellular Fluid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0300-483X(10)00667-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tox.2010.12.006</ArticleId>
            <ArticleId IdType="pubmed">21172400</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10578165</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0268-3369</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>24</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Bone marrow transplantation</Title>
                <ISOAbbreviation>Bone Marrow Transplant.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Encephalopathy complicating high-dose melphalan.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1141-3</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>High-dose melphalan (HDM) with peripheral blood stem cell transplant (PBSCT) is a common treatment for patients with multiple myeloma (MM) and more recently also with AL amyloidosis (ALA). We report two female patients with severe renal failure who underwent treatment with HDM for MM (patient 1) and ALA (patient 2). Both patients developed severe encephalopathy with generalised tonic-clonic seizures and a Glasgow Coma Scale (GCS) of 3/15. Causes for coma such as infections, metabolic disturbances, cerebral ischaemia or haemorrhage were excluded. Patient 1 died on day 25 post transplant while comatose. Patient 2 recovered from her comatose state 18 days after transplantation. To our knowledge this is the first report on a possible role of high-dose melphalan in the development of encephalopathy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schuh</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Haematology, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dandridge</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haydon</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Littlewood</LastName>
                    <ForeName>T J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Bone Marrow Transplant</MedlineTA>
            <NlmUniqueID>8702459</NlmUniqueID>
            <ISSNLinking>0268-3369</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q41OR9510P</RegistryNumber>
                <NameOfSubstance UI="D008558">Melphalan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000686">Amyloidosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018906">Antineoplastic Agents, Alkylating</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003128">Coma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004830">Epilepsy, Tonic-Clonic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015600">Glasgow Coma Scale</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008558">Melphalan</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10578165</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.bmt.1702041</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8870961</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>02</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>02</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0340-5761</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>70</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>1996</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of toxicology</Title>
                <ISOAbbreviation>Arch. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cyclophosphamide-induced apoptosis induces phocomelia in the mouse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>672-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Phocomelia (absence of upper fore and/or hind limbs) was induced in mouse fetuses using cyclophosphamide. On day 11 of gestation, pregnant mice were injected intraperitoneally with 10 ml/kg of saline containing cyclophosphamide (CP) at a dosage of 20 mg/kg body weight. On day 18, the fetuses were removed by Caesarean section from dams given CP on day 11 and were examined for external anomalies. Of 22 fetuses from CP-treated dams, 13 were dead or absorbed, but the surviving 9 fetuses were found to have phocomelia with various other external anomalies. In order to examine the direct cytotoxic effect of CP on fetal limb buds, fetuses were removed at 8, 16, 24, and 48 h after CP administration on day 11, revealing the presence of frequent pyknotic nuclei and apoptotic bodies in hematoxylin and eosin (H &amp; E) preparations. Cell-nuclei and apoptotic bodies were frequently observed by nick end-labeling in limb buds. Transmission electron microscopy demonstrated the typical changes of apoptosis. DNA extracted from the fetal limb buds submitted to CP was analysed by agarose gel electrophoresis, showing the ladder pattern characteristic of internucleosomal cleavage. These findings suggest that cyclophosphamide causes apoptosis in mouse fetal limb buds and that this process induces the external anomalies of phocomelia.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nomura</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Aichi Medical University, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikeda</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamura</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koike</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jie</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itoh</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY</Country>
            <MedlineTA>Arch Toxicol</MedlineTA>
            <NlmUniqueID>0417615</NlmUniqueID>
            <ISSNLinking>0340-5761</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.7.31</RegistryNumber>
                <NameOfSubstance UI="D004253">DNA Nucleotidylexotransferase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004253">DNA Nucleotidylexotransferase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004480">Ectromelia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005314">Embryonic and Fetal Development</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017403">In Situ Hybridization</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8870961</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10627661</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0960-3271</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Human &amp; experimental toxicology</Title>
                <ISOAbbreviation>Hum Exp Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Rapid lethal intoxication caused by the herbicide glyphosate-trimesium (Touchdown).</ArticleTitle>
            <Pagination>
                <MedlinePgn>735-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Two cases of rapid lethal intoxication with the herbicide glyphosate-trimesium (Touchdown) are presented. A 6-year-old boy who accidentally ingested a mouthful of glyphosate-trimesium died within minutes. The same happened to a 34-year-old woman who intentionally ingested approximately 150 ml of glyphosate-trimesium. The post-mortem examination revealed gastric content and oedema of the mucus membranes of the airways, erosion of the mucus membranes of the gastrointestinal tract, pulmonary oedema, cerebral oedema, and dilated right atrium and ventricle of the heart. The speed of which death occurs is much more rapid than lethal intoxications with the herbicide glyphosate (isoprophylamine), also known as 'Roundup'. It is suggested that the lethal mechanism between the two herbicides may be different. The component, trimethylsulfonium, of the glyphosate-trimesium may facilitate the absorption after oral ingestion. This difference can be crucial in the treatment of human intoxication. We propose that containers with glyphosate-trimesium must be labelled because of the apparent effect of lethal intoxication.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sorensen</LastName>
                    <ForeName>F W</ForeName>
                    <Initials>FW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Forensic Medicine, University of Aarhus, DK-8000 Aarhus C, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gregersen</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Hum Exp Toxicol</MedlineTA>
            <NlmUniqueID>9004560</NlmUniqueID>
            <ISSNLinking>0960-3271</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006540">Herbicides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C404484">N-(phosphonomethyl)glycine trimethylsulfonium salt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1071-83-6</RegistryNumber>
                <NameOfSubstance UI="C010974">glyphosate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>TE7660XO1C</RegistryNumber>
                <NameOfSubstance UI="D005998">Glycine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001929">Brain Edema</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004386">Duodenum</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004947">Esophagus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005753">Gastric Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005998">Glycine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006540">Herbicides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062025">Organophosphate Poisoning</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009943">Organophosphorus Compounds</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010614">Pharynx</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011654">Pulmonary Edema</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>3</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10627661</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3432520</PMID>
        <DateCreated>
            <Year>1988</Year>
            <Month>03</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1988</Year>
            <Month>03</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0033-3182</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>28</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>1987</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Psychosomatics</Title>
                <ISOAbbreviation>Psychosomatics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Visual hallucinations and suicidal ideation attributed to isosorbide dinitrate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>555-6</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rosenthal</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Psychosomatics</MedlineTA>
            <NlmUniqueID>0376506</NlmUniqueID>
            <ISSNLinking>0033-3182</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>IA7306519N</RegistryNumber>
                <NameOfSubstance UI="D007548">Isosorbide Dinitrate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000787">Angina Pectoris</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006212">Hallucinations</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007548">Isosorbide Dinitrate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013405">Suicide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014796">Visual Perception</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1987</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1987</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1987</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3432520</ArticleId>
            <ArticleId IdType="pii">S0033-3182(87)72471-2</ArticleId>
            <ArticleId IdType="doi">10.1016/S0033-3182(87)72471-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">5452657</PMID>
        <DateCreated>
            <Year>1970</Year>
            <Month>10</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1970</Year>
            <Month>10</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-4487</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>128</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1970</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annales médico-psychologiques</Title>
                <ISOAbbreviation>Ann Med Psychol (Paris)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Use of amitriptyline in syrup form in the treatment of enuresis amitriptyline in children].</ArticleTitle>
            <Pagination>
                <MedlinePgn>781-7</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Porot</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Girard</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Utilisation de l'amitriptyline sous sa forme sirop dans le traitement de l'énurésie de l'enfant.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>FRANCE</Country>
            <MedlineTA>Ann Med Psychol (Paris)</MedlineTA>
            <NlmUniqueID>2984692R</NlmUniqueID>
            <ISSNLinking>0003-4487</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014677">Pharmaceutical Vehicles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1806D8D52K</RegistryNumber>
                <NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000639">Amitriptyline</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004775">Enuresis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014677">Pharmaceutical Vehicles</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1970</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1970</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1970</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5452657</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16476808</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9942</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>63</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of neurology</Title>
                <ISOAbbreviation>Arch. Neurol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.</ArticleTitle>
            <Pagination>
                <MedlinePgn>205-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The threat of levodopa-induced dyskinesias often influences early treatment decisions in those with Parkinson disease.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the long-term risks of levodopa-associated dyskinesias of any severity, dyskinesias sufficient to require medication adjustment, and dyskinesias failing medication adjustments.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">The medical records linkage system of the Rochester Epidemiology Project was used to identify all incident Parkinson disease patients treated with levodopa (1976-1990). All records were independently reviewed by 2 neurologists who recorded demographic and drug data, dates when dyskinesias were initially identified, and dates when dyskinesias were sufficient to require medication changes; dyskinesias not controlled by drug adjustments were also tabulated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 126 incident Parkinson disease patients treated with levodopa for at least 2 months. By Kaplan-Meier analysis, the estimated rate of dyskinesias was 30% by 5 treatment years and 59% by 10 years. However, the rate of dyskinesias requiring medication adjustment was estimated to be only 17% by 5 years and 43% by 10 years. At 10 treatment years, the rate of dyskinesias that could not be controlled with medication adjustments was estimated at only 12%. An increased risk was associated with younger age and higher initial levodopa dose, but not with sex.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Levodopa-associated dyskinesias can be expected to develop in nearly 60% of patients in our community after 10 years, but these will be severe enough to require medication adjustments in only 43% of patients. At 10 treatment years, nearly 90% of these patients can expect to be spared dyskinesias that could not be controlled by drug adjustments. This population-based study suggests dyskinesia risk may not be a major concern for most Parkinson disease patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Van Gerpen</LastName>
                    <ForeName>Jay A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Ochsner Clinic, New Orleans, LA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumar</LastName>
                    <ForeName>Neeraj</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bower</LastName>
                    <ForeName>James H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weigand</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahlskog</LastName>
                    <ForeName>J Eric</ForeName>
                    <Initials>JE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AR 30582</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>NS 33978</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Arch Neurol</MedlineTA>
            <NlmUniqueID>0372436</NlmUniqueID>
            <ISSNLinking>0003-9942</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D008910">Minnesota</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">63/2/205</ArticleId>
            <ArticleId IdType="doi">10.1001/archneur.63.2.205</ArticleId>
            <ArticleId IdType="pubmed">16476808</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16476809</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9942</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>63</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of neurology</Title>
                <ISOAbbreviation>Arch. Neurol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>210-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Motor fluctuations are a common complication in patients with Parkinson disease (PD) receiving long-term levodopa therapy. Slowed gastric emptying and poor solubility of levodopa in the gastrointestinal tract may delay the onset of drug benefit after dosing. Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the efficacy, safety, and tolerability of etilevodopa in patients with PD who have motor fluctuations.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">A double-blind, randomized, comparative clinical trial.</AbstractText>
                <AbstractText Label="SETTING" NlmCategory="METHODS">Forty-four sites in the United States and Canada.</AbstractText>
                <AbstractText Label="PATIENTS" NlmCategory="METHODS">Three hundred twenty-seven patients with PD who had a latency of at least 90 minutes total daily time to &quot;on&quot; (TTON) after levodopa dosing.</AbstractText>
                <AbstractText Label="INTERVENTION" NlmCategory="METHODS">Treatment with either etilevodopa-carbidopa or levodopa-carbidopa for 18 weeks.</AbstractText>
                <AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Change from baseline in total daily TTON as measured using home diaries.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The reduction in mean total daily TTON from baseline to treatment was 0.58 hour in the etilevodopa-carbidopa group and 0.79 hour in the levodopa-carbidopa group (P = .24). There was no significant difference between the etilevodopa-carbidopa and levodopa-carbidopa groups in the reduction of response failures (-6.82% vs -4.69%; P = .20). Total daily &quot;off&quot; time improved in the etilevodopa-carbidopa (-0.85 hour) and levodopa-carbidopa (-0.87 hour) groups without an increase in on time with troublesome dyskinesias.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite the theoretical pharmacokinetic advantage of etilevodopa, there was no improvement in TTON, response failures, or off time compared with levodopa.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Blindauer</LastName>
                    <ForeName>Karen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA. kblindau@mcw.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shoulson</LastName>
                    <ForeName>Ira</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oakes</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kieburtz</LastName>
                    <ForeName>Karl</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwid</LastName>
                    <ForeName>Steven</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fahn</LastName>
                    <ForeName>Stanley</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stern</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goetz</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nutt</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goren</LastName>
                    <ForeName>Sari</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sayag</LastName>
                    <ForeName>Naim</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scolnik</LastName>
                    <ForeName>Marisa</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levy</LastName>
                    <ForeName>Ruth</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eyal</LastName>
                    <ForeName>Eli</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salzman</LastName>
                    <ForeName>Phyllis</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pagano</LastName>
                    <ForeName>Mary</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Parkinson Study Group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Arch Neurol</MedlineTA>
            <NlmUniqueID>0372436</NlmUniqueID>
            <ISSNLinking>0003-9942</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>895X917GYE</RegistryNumber>
                <NameOfSubstance UI="C481190">etilevodopa</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019957">Motor Skills Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011355">Prodrugs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011930">Reaction Time</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">63/2/210</ArticleId>
            <ArticleId IdType="doi">10.1001/archneur.63.2.210</ArticleId>
            <ArticleId IdType="pubmed">16476809</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2276694</PMID>
        <DateCreated>
            <Year>1991</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1991</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0278-6915</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>28</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title>
                <ISOAbbreviation>Food Chem. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation of promotion of pancreatic carcinogenesis in rats by benzyl acetate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>665-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Benzyl acetate was found to induce liver tumours and gastric squamous neoplasms in mice in a chronic bioassay conducted through the National Toxicology Program. An increased incidence of acinar cell adenomas of the pancreas of F344 rats was noted in the bioassay, but the significance of these lesions was confounded because the benzyl acetate was given by gavage in corn oil. The use of corn oil as a vehicle has been shown to enhance the growth of such lesions in the rat pancreas. The current studies were undertaken to evaluate benzyl acetate alone as an initiator and promoter of carcinogenesis in the pancreas. Alkaline elution analysis of acinar cell DNA showed no evidence of damage 1 hr after administration of benzyl acetate. Significant stimulation of growth of azaserine-induced foci was observed in a 6-month study, and a low but significant incidence of carcinoma in situ was observed in rats fed benzyl acetate in the diet for 2 yr. These experiments suggest that benzyl acetate is a weak promoter of the growth of carcinogen-induced and spontaneous pre-neoplastic foci in the pancreas.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Longnecker</LastName>
                    <ForeName>D S</ForeName>
                    <Initials>DS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Dartmouth Medical School, Hanover, NH 03756.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roebuck</LastName>
                    <ForeName>B D</ForeName>
                    <Initials>BD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curphey</LastName>
                    <ForeName>T J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>MacMillan</LastName>
                    <ForeName>D L</ForeName>
                    <Initials>DL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="N">
                <Grant>
                    <GrantID>CA 23108</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>ES-03283</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>ES-03687</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Food Chem Toxicol</MedlineTA>
            <NlmUniqueID>8207483</NlmUniqueID>
            <ISSNLinking>0278-6915</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001593">Benzyl Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0ECG3V79ZJ</RegistryNumber>
                <NameOfSubstance UI="C046412">benzyl acetate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8001-30-7</RegistryNumber>
                <NameOfSubstance UI="D003314">Corn Oil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>87299V3Q9W</RegistryNumber>
                <NameOfSubstance UI="D001377">Azaserine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-49-2</RegistryNumber>
                <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000236">Adenoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001377">Azaserine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001593">Benzyl Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016009">Chi-Square Distribution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003314">Corn Oil</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004247">DNA</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007676">Kidney Failure, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010179">Pancreas</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2276694</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18470320</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-6765</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>116</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Environmental health perspectives</Title>
                <ISOAbbreviation>Environ. Health Perspect.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prenatal organochlorine exposure and measures of behavior in infancy using the Neonatal Behavioral Assessment Scale (NBAS).</ArticleTitle>
            <Pagination>
                <MedlinePgn>666-73</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1289/ehp.10553</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous literature suggests an association between organochlorines and behavioral measures in childhood, including inattention.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study was designed to assess whether prenatal organochlorine exposure is associated with measures of attention in early infancy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We investigated an association between cord serum polychlorinated biphenyls (PCBs) and p,p'-dichlorodiphenyl dichloroethene (DDE) levels and measures of attention from the Neonatal Behavioral Assessment Scale (NBAS) in a cohort of 788 infants born 1993-1998 to mothers residing near a PCB-contaminated harbor and Superfund site in New Bedford, Massachusetts.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Medians (ranges) for the sum of four prevalent PCB congeners and DDE levels were 0.19 (0.01-4.41) and 0.30 (0-10.29) ng/g serum, respectively. For the 542 subjects with an NBAS exam at 2 weeks, we observed consistent inverse associations between cord serum PCB and DDE levels and NBAS measures of alertness, quality of alert responsiveness, cost of attention, and other potential attention-associated measures including self-quieting and motor maturity. For example, the decrement in quality of alert responsiveness score was -0.51 (95% confidence interval, -0.99 to -0.03) for the highest quartile of exposure to the sum of four prevalent PCB congeners compared with the lowest quartile. We found little evidence for an association with infant orientation, habituation, and regulation of state, assessed as summary cluster measures.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings provide evidence for an association between low-level prenatal PCB and DDE exposures and poor attention in early infancy. Further analyses will focus on whether organochlorine-associated decrements in attention and attention-related skills in infancy persist in later childhood.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sagiv</LastName>
                    <ForeName>Sharon K</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Environmental Health, Channing Laboratory, Harvard School of Public Health, Boston, MA 02115, USA. sharon.sagiv@channing.harvard.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nugent</LastName>
                    <ForeName>J Kevin</ForeName>
                    <Initials>JK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brazelton</LastName>
                    <ForeName>T Berry</ForeName>
                    <Initials>TB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Anna L</ForeName>
                    <Initials>AL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tolbert</LastName>
                    <ForeName>Paige E</ForeName>
                    <Initials>PE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Altshul</LastName>
                    <ForeName>Larisa M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korrick</LastName>
                    <ForeName>Susan A</ForeName>
                    <Initials>SA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P42 ES05947</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 MH073122</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Environ Health Perspect</MedlineTA>
            <NlmUniqueID>0330411</NlmUniqueID>
            <ISSNLinking>0091-6765</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004785">Environmental Pollutants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4M7FS82U08</RegistryNumber>
                <NameOfSubstance UI="D003633">Dichlorodiphenyl Dichloroethylene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DFC2HB4I0K</RegistryNumber>
                <NameOfSubstance UI="D011078">Polychlorinated Biphenyls</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2000 Jan;71(1 Suppl):300S-6S</RefSource>
                <PMID Version="1">10617986</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2000 Jan-Feb;22(1):21-9</RefSource>
                <PMID Version="1">10642111</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2000 Jun;108 Suppl 3:405-8</RefSource>
                <PMID Version="1">10852836</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Expo Anal Environ Epidemiol. 2000 Nov-Dec;10(6 Pt 2):743-54</RefSource>
                <PMID Version="1">11138666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 2000 Dec;21(6):1029-38</RefSource>
                <PMID Version="1">11233749</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2001 Jul 14;358(9276):110-4</RefSource>
                <PMID Version="1">11463412</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2001 Jul-Aug;23(4):305-17</RefSource>
                <PMID Version="1">11485834</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 2001 Nov 29;126(1-2):1-11</RefSource>
                <PMID Version="1">11704246</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Child Psychol Psychiatry. 2002 May;43(4):435-47</RefSource>
                <PMID Version="1">12030590</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2002 Nov;110(11):1113-7</RefSource>
                <PMID Version="1">12417482</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2003 Jan;111(1):65-70</RefSource>
                <PMID Version="1">12515680</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychoneuroendocrinology. 2003 Apr;28(3):304-16</RefSource>
                <PMID Version="1">12573298</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr. 2003 Dec;143(6):780-8</RefSource>
                <PMID Version="1">14657828</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychology. 2004 Jan;18(1):185-93</RefSource>
                <PMID Version="1">14744201</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Obstet Gynecol. 1973 Sep 1;117(1):1-9</RefSource>
                <PMID Version="1">4722373</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Orthopsychiatry. 1978 Jan;48(1):140-7</RefSource>
                <PMID Version="1">623213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Monogr Soc Res Child Dev. 1978;43(5-6):46-59</RefSource>
                <PMID Version="1">752804</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Child Dev. 1982 Jun;53(3):687-92</RefSource>
                <PMID Version="1">7094677</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr. 1984 Aug;105(2):315-20</RefSource>
                <PMID Version="1">6431068</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Child Dev. 1985 Feb;56(1):15-27</RefSource>
                <PMID Version="1">3987400</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Child Dev. 1985 Aug;56(4):853-60</RefSource>
                <PMID Version="1">3930167</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr. 1986 Aug;109(2):335-41</RefSource>
                <PMID Version="1">3090217</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dev Behav Pediatr. 1987 Feb;8(1):39-50</RefSource>
                <PMID Version="1">3546383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Med Child Neurol. 2003 Aug;45(8):525-35</RefSource>
                <PMID Version="1">12882531</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Dis Child. 2003 Oct;88(10):904-10</RefSource>
                <PMID Version="1">14500312</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Scand J Psychol. 1989;30(3):161-7</RefSource>
                <PMID Version="1">2587964</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 1990 May;85(5):801-7</RefSource>
                <PMID Version="1">2330243</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 1993 Jan;91(1):113-20</RefSource>
                <PMID Version="1">8416473</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1993 Apr 8;328(14):997-1001</RefSource>
                <PMID Version="1">8450877</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Phys Med Biol. 1995 Sep;40(9):1475-85</RefSource>
                <PMID Version="1">8532760</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dev Behav Pediatr. 1995 Dec;16(6):406-11</RefSource>
                <PMID Version="1">8746549</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1996 Sep 12;335(11):783-9</RefSource>
                <PMID Version="1">8703183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1996 Jun 3;723(1-2):23-8</RefSource>
                <PMID Version="1">8813378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1997 Sep;146(1):95-103</RefSource>
                <PMID Version="1">9299601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Psychiatr Res. 1997 May-Jun;31(3):359-63</RefSource>
                <PMID Version="1">9306293</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Ind Health. 1998 Jan-Apr;14(1-2):85-101</RefSource>
                <PMID Version="1">9460171</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Folia Phoniatr Logop. 1998;50(3):107-17</RefSource>
                <PMID Version="1">9691527</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 1998 Jul;94(1):213-24</RefSource>
                <PMID Version="1">9708851</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Psychiatry. 1998 Nov 15;44(10):951-8</RefSource>
                <PMID Version="1">9821559</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1998 Dec;106(12):775-92</RefSource>
                <PMID Version="1">9831538</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Med Child Neurol. 1998 Dec;40(12):796-804</RefSource>
                <PMID Version="1">9881675</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 2005 Apr 30;159(2):323-31</RefSource>
                <PMID Version="1">15817195</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 2005 Sep;16(5):648-56</RefSource>
                <PMID Version="1">16135941</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health. 2005;4:22</RefSource>
                <PMID Version="1">16236166</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2005 Nov-Dec;27(6):771-80</RefSource>
                <PMID Version="1">16198536</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Brain Behav. 2006 Apr;5(3):282-97</RefSource>
                <PMID Version="1">16594981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2006 Oct;93(2):223-41</RefSource>
                <PMID Version="1">16829543</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 2007 Jan;18(1):120-9</RefSource>
                <PMID Version="1">17179760</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chemosphere. 2007 Apr;67(9):S412-20</RefSource>
                <PMID Version="1">17223178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Endocrinol (Oxf). 2007 Jun;66(6):890-8</RefSource>
                <PMID Version="1">17535399</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2003 Mar;111(3):357-576</RefSource>
                <PMID Version="1">12611666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Dev. 2003 Aug;25(5):313-21</RefSource>
                <PMID Version="1">12850509</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2003 Oct;111(13):1670-7</RefSource>
                <PMID Version="1">14527849</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Epidemiol Community Health. 2003 Oct;57(10):778-83</RefSource>
                <PMID Version="1">14573579</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001288">Attention</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003633">Dichlorodiphenyl Dichloroethylene</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004781">Environmental Exposure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004785">Environmental Pollutants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018730">Infant Behavior</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D008404">Massachusetts</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011078">Polychlorinated Biphenyls</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2367684</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">behavior</Keyword>
            <Keyword MajorTopicYN="N">infant</Keyword>
            <Keyword MajorTopicYN="N">organochlorines</Keyword>
            <Keyword MajorTopicYN="N">p,p′-dichlorodiphenyl dichloroethene (DDE)</Keyword>
            <Keyword MajorTopicYN="N">poly-chlorinated biphenyls (PCBs)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1289/ehp.10553</ArticleId>
            <ArticleId IdType="pubmed">18470320</ArticleId>
            <ArticleId IdType="pmc">PMC2367684</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8483331</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>06</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>06</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0887-6924</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1993</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Leukemia</Title>
                <ISOAbbreviation>Leukemia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Erythema nodosum associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>758-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A patient with acute promyelocytic leukemia is presented. During treatment with all-trans-retinoic acid, erythema nodosum developed. Treatment with all-trans-retinoic acid was continued, the erythema nodosum resolved with steroid treatment, and a complete remission was attained. This case is the first report of erythema nodosum associated with all-trans-retinoic acid.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hakimian</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tallman</LastName>
                    <ForeName>M S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zugerman</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caro</LastName>
                    <ForeName>W A</ForeName>
                    <Initials>WA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Leukemia</MedlineTA>
            <NlmUniqueID>8704895</NlmUniqueID>
            <ISSNLinking>0887-6924</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>5688UTC01R</RegistryNumber>
                <NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004893">Erythema Nodosum</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015473">Leukemia, Promyelocytic, Acute</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8483331</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9915363</PMID>
        <DateCreated>
            <Year>1999</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1999</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-3022</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>90</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anesthesiology</Title>
                <ISOAbbreviation>Anesthesiology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Perioperative extrapyramidal reactions associated with ondansetron.</ArticleTitle>
            <Pagination>
                <MedlinePgn>340-1</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tolan</LastName>
                    <ForeName>M M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fuhrman</LastName>
                    <ForeName>T M</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsueda</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lippmann</LastName>
                    <ForeName>S B</ForeName>
                    <Initials>SB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Anesthesiology</MedlineTA>
            <NlmUniqueID>1300217</NlmUniqueID>
            <ISSNLinking>0003-3022</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000932">Antiemetics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4AF302ESOS</RegistryNumber>
                <NameOfSubstance UI="D017294">Ondansetron</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000932">Antiemetics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001480">Basal Ganglia Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002763">Cholecystectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017294">Ondansetron</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>1</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>1</Month>
                <Day>23</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>1</Month>
                <Day>23</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9915363</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17495784</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>05</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1528-1159</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>32</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>May</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Spine</Title>
                <ISOAbbreviation>Spine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cervical transforaminal epidural steroid injections: more dangerous than we think?</ArticleTitle>
            <Pagination>
                <MedlinePgn>1249-56</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Survey/case series.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To survey pain physicians about neurologic infarctions following cervical transforaminal epidural steroid injections (TF-ESIs).</AbstractText>
                <AbstractText Label="SUMMARY OF BACKGROUND DATA" NlmCategory="BACKGROUND">Cervical TF-ESIs are commonly performed in patients with cervical radiculopathy, although there are no randomized controlled studies supporting their efficacy. Eight case reports of brain and spinal cord infarction have been published. In addition, one of the investigators (M.S.W.) has reviewed 4 cases of major cerebellum/brainstem infarction following cervical TF-ESIs with methylprednisolone.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">To better characterize these complications, anonymous surveys were sent to all U.S. physician members of the American Pain Society. Respondents were asked about awareness of complications, year of occurrence, practice setting and specialty of the treating physician, use of fluoroscopy/contrast/local anesthetic/corticosteroid, doses administered, and CT/MRI/autopsy findings.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall response rate was 21.4% (287 of 1340). In all, 78 complications were reported, including 16 vertebrobasilar brain infarcts, 12 cervical spinal cord infarcts, and 2 combined brain/spinal cord infarcts. Brain infarcts invariably involved the cerebellum, brainstem, or posterior cerebral artery territory. Thirteen cases resulted in a fatal outcome: 5 with brain infarcts, 1 with combined brain/spinal cord infarcts, 1 following high spinal anesthesia, 1 associated with a seizure, and 5 with unspecified etiology. All 4 cases with corticosteroid alone involved methylprednisolone, resulting in 3 cerebellar infarcts and 1 posterior cerebral territory infarct. Of these, 3 had fatal outcomes and 2 autopsies revealed no vertebral artery trauma.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates a significant risk of serious neurologic injury after cervical TF-ESIs. A growing body of evidence supports an embolic mechanism, whereby inadvertent intra-arterial injection of particulate corticosteroid causes a distal infarct. Embolism to the distal basilar artery region can cause midbrain, pons, cerebellum, thalamus, temporal and occipital lobe infarctions. Other potential mechanisms of infarction include vertebral artery perforation causing dissection/thrombosis and needle-induced vasospasm.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Scanlon</LastName>
                    <ForeName>Graham C</ForeName>
                    <Initials>GC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Pain and Palliative Medicine, Department of Anesthesiology, University of California, San Diego, La Jolla, CA 92093-0924, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moeller-Bertram</LastName>
                    <ForeName>Tobias</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Romanowsky</LastName>
                    <ForeName>Shawn M</ForeName>
                    <Initials>SM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wallace</LastName>
                    <ForeName>Mark S</ForeName>
                    <Initials>MS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Spine (Phila Pa 1976)</MedlineTA>
            <NlmUniqueID>7610646</NlmUniqueID>
            <ISSNLinking>0362-2436</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>X4W7ZR7023</RegistryNumber>
                <NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Spine (Phila Pa 1976). 2007 Nov 1;32(23):2638</RefSource>
                <PMID Version="1">17978668</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000305">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020520">Brain Infarction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D002574">Cervical Vertebrae</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007268">Injections, Epidural</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008775">Methylprednisolone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011843">Radiculopathy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013119">Spinal Cord Injuries</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BRS.0b013e318053ec50</ArticleId>
            <ArticleId IdType="pii">00007632-200705150-00016</ArticleId>
            <ArticleId IdType="pubmed">17495784</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16917115</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>10</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>12</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1073-449X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>174</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Nov</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of respiratory and critical care medicine</Title>
                <ISOAbbreviation>Am. J. Respir. Crit. Care Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1042-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Rebound pulmonary hypertension (PHT) can complicate the weaning of nitric oxide (NO), and is in part related to transient depletion of intrinsic cyclic guanosine monophosphate. Rebound is characterized by increased pulmonary arterial (PA) pressure, cardiopulmonary instability, and in some cases, the need to continue NO beyond the intended period of use. There is anecdotal evidence that sildenafil, a phosphodiesterase-5 inhibitor, may prevent recurrence of rebound.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We investigated the role of sildenafil in preventing rebound (an increase in PA pressure of 20% or greater, or failure to discontinue NO) in patients in whom previous attempts had not been made to wean from NO.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty ventilated infants and children, receiving 10 ppm or greater inhaled NO, were randomized to receive 0.4 mg/kg of sildenafil, or placebo, 1 h before discontinuing NO. Twenty-nine patients completed the study.</AbstractText>
                <AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">PA pressures and blood gases were measured before the study drug, and 1 and 4 h after stopping NO.</AbstractText>
                <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Rebound occurred in 10 of 14 placebo patients, and 0 of 15 sildenafil patients (p &lt; 0.001). PA pressure increased by 25% (14-67) in placebo patients, and by 1%(-9-5) in sildenafil patients (p &lt; 0.001). Four placebo patients could not be weaned from NO due to severe cardiovascular instability, whereas all sildenafil patients were weaned (p = 0.042). Duration of ventilation after study was 98.0 (47.0-223.5) h for placebo patients and 28.2 (15.7-54.6) h for sildenafil patients (p = 0.024).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A single dose of sildenafil prevented rebound after withdrawal of NO, and reduced the duration of mechanical ventilation. Prophylaxis with sildenafil should be considered when weaning patients from inhaled NO.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Namachivayam</LastName>
                    <ForeName>Poongundran</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Intensive Care, The Royal Children's Hospital, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Theilen</LastName>
                    <ForeName>Ulf</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Butt</LastName>
                    <ForeName>Warwick W</ForeName>
                    <Initials>WW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>Sian M</ForeName>
                    <Initials>SM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Penny</LastName>
                    <ForeName>Daniel J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shekerdemian</LastName>
                    <ForeName>Lara S</ForeName>
                    <Initials>LS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2006</Year>
                <Month>08</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Respir Crit Care Med</MedlineTA>
            <NlmUniqueID>9421642</NlmUniqueID>
            <ISSNLinking>1073-449X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013450">Sulfones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3M7OB98Y7H</RegistryNumber>
                <NameOfSubstance UI="C101426">sildenafil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000280">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006330">Heart Defects, Congenital</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006976">Hypertension, Pulmonary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010726">Phosphodiesterase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011651">Pulmonary Artery</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011687">Purines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012121">Respiration, Artificial</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013450">Sulfones</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>12</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">200605-694OC</ArticleId>
            <ArticleId IdType="doi">10.1164/rccm.200605-694OC</ArticleId>
            <ArticleId IdType="pubmed">16917115</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20555330</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>08</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>01</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1348-4214</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>33</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hypertension research : official journal of the Japanese Society of Hypertension</Title>
                <ISOAbbreviation>Hypertens. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.</ArticleTitle>
            <Pagination>
                <MedlinePgn>796-801</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/hr.2010.107</ELocationID>
            <Abstract>
                <AbstractText>Telmisartan, a selective antagonist for angiotensin type1 receptor and a partial agonist for peroxisome proliferator-activated receptor-gamma, decreases blood pressure and has been shown to improve glucose and lipid metabolism, suggesting potential cardiovascular protective effects. In this study, we investigated whether long-term treatment with telmisartan improved endothelial function in 35 hypertensive patients with type 2 diabetes mellitus (T2DM). Office and home early morning blood pressure levels and flow-mediated vasodilation (FMD) were evaluated before and after 12 months of treatment with telmisartan. Blood samples were also obtained for measurement of several biochemical parameters and of adiponectin (AN) and highly sensitive C-reactive protein (hs-CRP) before and after treatment. After 12 months of treatment, office and morning blood pressure levels had significantly decreased, and levels of plasma glucose, glycosylated hemoglobin, total cholesterol, triglyceride and low-density lipoprotein cholesterol had also significantly decreased. Plasma AN and high-density lipoprotein cholesterol levels increased, but hs-CRP levels decreased. Furthermore, FMD significantly increased; changes in percent FMD showed a significant negative correlation with changes in systolic and diastolic blood pressure and a significant positive correlation with changes in AN. Stepwise multivariate regression analysis revealed that changes in plasma AN and office systolic blood pressure were both independent determinants for endothelial function after telmisartan treatment. In conclusion, this study shows that long-term treatment with telmisartan improves not only blood pressure and glucose and lipid metabolism but also endothelial function in hypertensive patients with T2DM, possibly by increased circulating AN and decreased blood pressure.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wago</LastName>
                    <ForeName>Takehiko</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshimoto</LastName>
                    <ForeName>Takanobu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akaza</LastName>
                    <ForeName>Itaru</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsuchiya</LastName>
                    <ForeName>Kyoichiro</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Izumiyama</LastName>
                    <ForeName>Hajime</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doi</LastName>
                    <ForeName>Masaru</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirata</LastName>
                    <ForeName>Yukio</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>06</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hypertens Res</MedlineTA>
            <NlmUniqueID>9307690</NlmUniqueID>
            <ISSNLinking>0916-9636</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C499918">ADIPOQ protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D052242">Adiponectin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001565">Benzoates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-41-4</RegistryNumber>
                <NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U5SYW473RQ</RegistryNumber>
                <NameOfSubstance UI="C084178">telmisartan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Hypertens Res. 2010 Aug;33(8):780-1</RefSource>
                <PMID Version="1">20555332</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D052242">Adiponectin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047228">Angiotensin II Type 1 Receptor Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001562">Benzimidazoles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001565">Benzoates</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002097">C-Reactive Protein</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004730">Endothelium, Vascular</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008055">Lipids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014664">Vasodilation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">hr2010107</ArticleId>
            <ArticleId IdType="doi">10.1038/hr.2010.107</ArticleId>
            <ArticleId IdType="pubmed">20555330</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11191693</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1044-5463</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>10</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Season>Winter</Season>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of child and adolescent psychopharmacology</Title>
                <ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sudden death of a child treated with imipramine. Case study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>321-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Since 1990, there have been seven reported cases of sudden death in children treated with tricyclic antidepressants. This case study describes the sudden death of an additional child (8 years 9 months old, 29 kg in weight) treated with a tricyclic antidepressant, imipramine (100 mg orally, twice daily), and dextroamphetamine (10 mg orally every morning). Prior to death, there were signs of possible cardiovascular abnormalities after treatment was begun with imipramine. The report adds to the concern over the use of tricyclics in children.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Varley</LastName>
                    <ForeName>C K</ForeName>
                    <Initials>CK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Child and Adolescent Psychiatry, University of Washington, Seattle 98105, USA. Cvarley@u.washington.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA>
            <NlmUniqueID>9105358</NlmUniqueID>
            <ISSNLinking>1044-5463</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>OGG85SX4E4</RegistryNumber>
                <NameOfSubstance UI="D007099">Imipramine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>TZ47U051FI</RegistryNumber>
                <NameOfSubstance UI="D003913">Dextroamphetamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000929">Antidepressive Agents, Tricyclic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001145">Arrhythmias, Cardiac</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000697">Central Nervous System Stimulants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003645">Death, Sudden</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003913">Dextroamphetamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006323">Heart Arrest</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007099">Imipramine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>12</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>12</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11191693</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10989779</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>01</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>02</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0899-3289</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2000</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of substance abuse</Title>
                <ISOAbbreviation>J Subst Abuse</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>205-13</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This report examined a broad range of cognitive functioning in a group of recently abstinent, cocaine-abusing schizophrenic patients (CA + SZ).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Measures of selective and sustained attention, learning and memory, and executive functioning were administered to CA + SZ patients within 72 h of last cocaine use. A comparison group of non-substance-abusing schizophrenic patients (SZ) presenting for inpatient psychiatric treatment were also examined in an identical time frame. We hypothesized that the neurobiological impact of cocaine abuse and acute abstinence would cause CA + SZ to manifest deficits in all domains of cognitive functioning relative to non-abusing SZ patients.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Results revealed that CA + SZ displayed significant memory impairment relative to their non-abuser SZ counterparts. No group differences, however, were detected on any other neurocognitive measure. CA + SZ were able to selectively process digit strings during the presence and absence of distracting stimuli, sustain attention, and perform executive functions at performance levels equal to their non-abuser SZ counterparts.</AbstractText>
                <AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">These results are consistent with many past studies that have found CA + SZ patients to manifest memory impairment but have relatively well preserved functioning in other cognitive domains. The results are discussed in terms of the biological concomitants of cocaine abuse and acute abstinence in schizophrenia.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Serper</LastName>
                    <ForeName>M R</ForeName>
                    <Initials>MR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychology, Hofstra University, Hempstead, NY 11549-1270, USA. mark.serper@nyu.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Copersino</LastName>
                    <ForeName>M L</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richarme</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vadhan</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cancro</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Subst Abuse</MedlineTA>
            <NlmUniqueID>9001404</NlmUniqueID>
            <ISSNLinking>0899-3289</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001288">Attention</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000534">rehabilitation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011939">Mental Recall</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009483">Neuropsychological Tests</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000534">rehabilitation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D012565">Schizophrenic Psychology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012691">Serial Learning</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014706">Verbal Learning</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>3</Month>
                <Day>3</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10989779</ArticleId>
            <ArticleId IdType="pii">S0899-3289(00)00021-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23143595</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1316-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2469</ELocationID>
            <Abstract>
                <AbstractText>Burkitt lymphoma is a mature aggressive B-cell lymphoma derived from germinal center B cells. Its cytogenetic hallmark is the Burkitt translocation t(8;14)(q24;q32) and its variants, which juxtapose the MYC oncogene with one of the three immunoglobulin loci. Consequently, MYC is deregulated, resulting in massive perturbation of gene expression. Nevertheless, MYC deregulation alone seems not to be sufficient to drive Burkitt lymphomagenesis. By whole-genome, whole-exome and transcriptome sequencing of four prototypical Burkitt lymphomas with immunoglobulin gene (IG)-MYC translocation, we identified seven recurrently mutated genes. One of these genes, ID3, mapped to a region of focal homozygous loss in Burkitt lymphoma. In an extended cohort, 36 of 53 molecularly defined Burkitt lymphomas (68%) carried potentially damaging mutations of ID3. These were strongly enriched at somatic hypermutation motifs. Only 6 of 47 other B-cell lymphomas with the IG-MYC translocation (13%) carried ID3 mutations. These findings suggest that cooperation between ID3 inactivation and IG-MYC translocation is a hallmark of Burkitt lymphomagenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Richter</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Human Genetics, Christian-Albrechts-University, Kiel, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schlesner</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffmann</LastName>
                    <ForeName>Steve</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kreuz</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leich</LastName>
                    <ForeName>Ellen</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burkhardt</LastName>
                    <ForeName>Birgit</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosolowski</LastName>
                    <ForeName>Maciej</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ammerpohl</LastName>
                    <ForeName>Ole</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wagener</LastName>
                    <ForeName>Rabea</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernhart</LastName>
                    <ForeName>Stephan H</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lenze</LastName>
                    <ForeName>Dido</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Szczepanowski</LastName>
                    <ForeName>Monika</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paulsen</LastName>
                    <ForeName>Maren</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lipinski</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Russell</LastName>
                    <ForeName>Robert B</ForeName>
                    <Initials>RB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adam-Klages</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Apic</LastName>
                    <ForeName>Gordana</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Claviez</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasenclever</LastName>
                    <ForeName>Dirk</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hovestadt</LastName>
                    <ForeName>Volker</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hornig</LastName>
                    <ForeName>Nadine</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korbel</LastName>
                    <ForeName>Jan O</ForeName>
                    <Initials>JO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kube</LastName>
                    <ForeName>Dieter</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langenberger</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawerenz</LastName>
                    <ForeName>Chris</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lisfeld</LastName>
                    <ForeName>Jasmin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meyer</LastName>
                    <ForeName>Katharina</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Picelli</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pischimarov</LastName>
                    <ForeName>Jordan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Radlwimmer</LastName>
                    <ForeName>Bernhard</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rausch</LastName>
                    <ForeName>Tobias</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rohde</LastName>
                    <ForeName>Marius</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schilhabel</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scholtysik</LastName>
                    <ForeName>René</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spang</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trautmann</LastName>
                    <ForeName>Heiko</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zenz</LastName>
                    <ForeName>Thorsten</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borkhardt</LastName>
                    <ForeName>Arndt</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drexler</LastName>
                    <ForeName>Hans G</ForeName>
                    <Initials>HG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Möller</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>MacLeod</LastName>
                    <ForeName>Roderick A F</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pott</LastName>
                    <ForeName>Christiane</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schreiber</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trümper</LastName>
                    <ForeName>Lorenz</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loeffler</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stadler</LastName>
                    <ForeName>Peter F</ForeName>
                    <Initials>PF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lichter</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eils</LastName>
                    <ForeName>Roland</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Küppers</LastName>
                    <ForeName>Ralf</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hummel</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klapper</LastName>
                    <ForeName>Wolfram</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenstiel</LastName>
                    <ForeName>Philip</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenwald</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brors</LastName>
                    <ForeName>Benedikt</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siebert</LastName>
                    <ForeName>Reiner</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>ICGC MMML-Seq Project</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GEO</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>GSE10172</AccessionNumber>
                        <AccessionNumber>GSE22470</AccessionNumber>
                        <AccessionNumber>GSE4475</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051796">Inhibitor of Differentiation Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>147785-34-0</RegistryNumber>
                <NameOfSubstance UI="C075640">ID3 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002051">Burkitt Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002874">Chromosome Mapping</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002883">Chromosomes, Human, Pair 14</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002898">Chromosomes, Human, Pair 8</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005803">Genes, Immunoglobulin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016259">Genes, myc</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051796">Inhibitor of Differentiation Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D027041">Somatic Hypermutation, Immunoglobulin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014178">Translocation, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Ammerpohl</LastName>
                <ForeName>Ole</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Claviez</LastName>
                <ForeName>Alexander</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Esser</LastName>
                <ForeName>Daniela</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hornig</LastName>
                <ForeName>Nadine</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klapper</LastName>
                <ForeName>Wolfram</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pott</LastName>
                <ForeName>Christiane</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Richter</LastName>
                <ForeName>Gesine</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Richter</LastName>
                <ForeName>Julia</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosenstiel</LastName>
                <ForeName>Philip</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schilhabel</LastName>
                <ForeName>Markus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schreiber</LastName>
                <ForeName>Stefan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siebert</LastName>
                <ForeName>Reiner</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hemmrich-Stanisak</LastName>
                <ForeName>Georg</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Szczepanowski</LastName>
                <ForeName>Monika</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trautmann</LastName>
                <ForeName>Heiko</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wagener</LastName>
                <ForeName>Rabea</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ebert</LastName>
                <ForeName>Sonja</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kube</LastName>
                <ForeName>Dieter</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meyer</LastName>
                <ForeName>Katharina</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trümper</LastName>
                <ForeName>Lorenz</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burkhardt</LastName>
                <ForeName>Birgit</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lisfeld</LastName>
                <ForeName>Jasmin</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rohde</LastName>
                <ForeName>Marius</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brors</LastName>
                <ForeName>Benedikt</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eils</LastName>
                <ForeName>Jürgen</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eils</LastName>
                <ForeName>Roland</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hutter</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jäger</LastName>
                <ForeName>Natalie</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Korbel</LastName>
                <ForeName>Jan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lawerenz</LastName>
                <ForeName>Chris</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lichter</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Radlwimmer</LastName>
                <ForeName>Bernhard</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Radomski</LastName>
                <ForeName>Sylwester</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schlesner</LastName>
                <ForeName>Matthias</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scholz</LastName>
                <ForeName>Ingrid</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zenz</LastName>
                <ForeName>Thorsten</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Möller</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lenze</LastName>
                <ForeName>Dido</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hummel</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leich</LastName>
                <ForeName>Ellen</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pischimarov</LastName>
                <ForeName>Jordan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosenwald</LastName>
                <ForeName>Andreas</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Binder</LastName>
                <ForeName>Vera</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Borkhardt</LastName>
                <ForeName>Arndt</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoell</LastName>
                <ForeName>Jessica</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hezaveh</LastName>
                <ForeName>Kebria</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bernhart</LastName>
                <ForeName>Stephan H</ForeName>
                <Initials>SH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Binder</LastName>
                <ForeName>Hans</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoffmann</LastName>
                <ForeName>Steve</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hopp</LastName>
                <ForeName>Lydia</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kreuz</LastName>
                <ForeName>Markus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Langenberger</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loeffler</LastName>
                <ForeName>Markus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosolowski</LastName>
                <ForeName>Maciej</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stadler</LastName>
                <ForeName>Peter F</ForeName>
                <Initials>PF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hansmann</LastName>
                <ForeName>Martin-Leo</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Küppers</LastName>
                <ForeName>Ralf</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weniger</LastName>
                <ForeName>Marc</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scholtysik</LastName>
                <ForeName>Rene</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spang</LastName>
                <ForeName>Rainer</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barth</LastName>
                <ForeName>Thomas F E</ForeName>
                <Initials>TF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bernd</LastName>
                <ForeName>Heinz-Wolfram</ForeName>
                <Initials>HW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cogliatti</LastName>
                <ForeName>Sergio B</ForeName>
                <Initials>SB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Feller</LastName>
                <ForeName>Alfred C</ForeName>
                <Initials>AC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hansmann</LastName>
                <ForeName>Martin L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hummel</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klapper</LastName>
                <ForeName>Wolfram</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Möller</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Müller-Hermelink</LastName>
                <ForeName>Hans-Konrad</ForeName>
                <Initials>HK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ott</LastName>
                <ForeName>German</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stein</LastName>
                <ForeName>Harald</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Szczepanowski</LastName>
                <ForeName>Monika</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wacker</LastName>
                <ForeName>Hans-Heinrich</ForeName>
                <Initials>HH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barth</LastName>
                <ForeName>Thomas F E</ForeName>
                <Initials>TF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Behrmann</LastName>
                <ForeName>Petra</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Daniel</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dierlammm</LastName>
                <ForeName>Judith</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Haralambieva</LastName>
                <ForeName>Eugenia</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harder</LastName>
                <ForeName>Lana</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Holterhus</LastName>
                <ForeName>Paul-Martin</ForeName>
                <Initials>PM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Küppers</LastName>
                <ForeName>Ralf</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kube</LastName>
                <ForeName>Dieter</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lichter</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martín-Subero</LastName>
                <ForeName>Jose I</ForeName>
                <Initials>JI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Möller</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murga-Peñas</LastName>
                <ForeName>Eva M</ForeName>
                <Initials>EM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pscherer</LastName>
                <ForeName>Armin</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosenwald</LastName>
                <ForeName>Andreas</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schwaenen</LastName>
                <ForeName>Carsten</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siebert</LastName>
                <ForeName>Reiner</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trautmann</LastName>
                <ForeName>Heiko</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vockerodt</LastName>
                <ForeName>Martina</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wessendorf</LastName>
                <ForeName>Swen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bentink</LastName>
                <ForeName>Stefan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berger</LastName>
                <ForeName>Hilmar</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hasenclever</LastName>
                <ForeName>Dirk</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kreuz</LastName>
                <ForeName>Markus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loeffler</LastName>
                <ForeName>Markus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosolowski</LastName>
                <ForeName>Maciej</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spang</LastName>
                <ForeName>Rainer</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stürzenhofecker</LastName>
                <ForeName>Benjamin</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trümper</LastName>
                <ForeName>Lorenz</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wehner</LastName>
                <ForeName>Maren</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loeffler</LastName>
                <ForeName>Markus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siebert</LastName>
                <ForeName>Reiner</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stein</LastName>
                <ForeName>Harald</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trümper</LastName>
                <ForeName>Lorenz</ForeName>
                <Initials>L</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>4</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2469</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2469</ArticleId>
            <ArticleId IdType="pubmed">23143595</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23143596</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1336-40</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2462</ELocationID>
            <Abstract>
                <AbstractText>Using the Immunochip custom SNP array, which was designed for dense genotyping of 186 loci identified through genome-wide association studies (GWAS), we analyzed 11,475 individuals with rheumatoid arthritis (cases) of European ancestry and 15,870 controls for 129,464 markers. We combined these data in a meta-analysis with GWAS data from additional independent cases (n = 2,363) and controls (n = 17,872). We identified 14 new susceptibility loci, 9 of which were associated with rheumatoid arthritis overall and five of which were specifically associated with disease that was positive for anticitrullinated peptide antibodies, bringing the number of confirmed rheumatoid arthritis risk loci in individuals of European ancestry to 46. We refined the peak of association to a single gene for 19 loci, identified secondary independent effects at 6 loci and identified association to low-frequency variants at 4 loci. Bioinformatic analyses generated strong hypotheses for the causal SNP at seven loci. This study illustrates the advantages of dense SNP mapping analysis to inform subsequent functional investigations.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Eyre</LastName>
                    <ForeName>Steve</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowes</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Diogo</LastName>
                    <ForeName>Dorothée</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Annette</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barton</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhernakova</LastName>
                    <ForeName>Alexandra</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stahl</LastName>
                    <ForeName>Eli</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Viatte</LastName>
                    <ForeName>Sebastien</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McAllister</LastName>
                    <ForeName>Kate</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amos</LastName>
                    <ForeName>Christopher I</ForeName>
                    <Initials>CI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Padyukov</LastName>
                    <ForeName>Leonid</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toes</LastName>
                    <ForeName>Rene E M</ForeName>
                    <Initials>RE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huizinga</LastName>
                    <ForeName>Tom W J</ForeName>
                    <Initials>TW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wijmenga</LastName>
                    <ForeName>Cisca</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trynka</LastName>
                    <ForeName>Gosia</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franke</LastName>
                    <ForeName>Lude</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Westra</LastName>
                    <ForeName>Harm-Jan</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alfredsson</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Xinli</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sandor</LastName>
                    <ForeName>Cynthia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Bakker</LastName>
                    <ForeName>Paul I W</ForeName>
                    <Initials>PI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davila</LastName>
                    <ForeName>Sonia</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khor</LastName>
                    <ForeName>Chiea Chuen</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heng</LastName>
                    <ForeName>Khai Koon</ForeName>
                    <Initials>KK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andrews</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Edkins</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hunt</LastName>
                    <ForeName>Sarah E</ForeName>
                    <Initials>SE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langford</LastName>
                    <ForeName>Cordelia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Symmons</LastName>
                    <ForeName>Deborah</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Wellcome Trust Case Control Consortium</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Concannon</LastName>
                    <ForeName>Pat</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Onengut-Gumuscu</LastName>
                    <ForeName>Suna</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rich</LastName>
                    <ForeName>Stephen S</ForeName>
                    <Initials>SS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deloukas</LastName>
                    <ForeName>Panos</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez-Gay</LastName>
                    <ForeName>Miguel A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rodriguez-Rodriguez</LastName>
                    <ForeName>Luis</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ärlsetig</LastName>
                    <ForeName>Lisbeth</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Javier</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rantapää-Dahlqvist</LastName>
                    <ForeName>Solbritt</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plenge</LastName>
                    <ForeName>Robert M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raychaudhuri</LastName>
                    <ForeName>Soumya</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klareskog</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gregersen</LastName>
                    <ForeName>Peter K</ForeName>
                    <Initials>PK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Worthington</LastName>
                    <ForeName>Jane</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>068545/Z/02</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>076113/C/04/Z</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>090532</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>091157</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>17552</GrantID>
                    <Agency>Arthritis Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>17552</GrantID>
                    <Agency>Arthritis Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>18475</GrantID>
                    <Agency>Arthritis Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>1R01AR062886-01</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CZB/4/540</GrantID>
                    <Agency>Chief Scientist Office</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>ETM/137</GrantID>
                    <Agency>Chief Scientist Office</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>ETM/75</GrantID>
                    <Agency>Chief Scientist Office</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0000934</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0600329</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0800759</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>K08AR055688</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U147585819</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_UP_A620_1014</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>N01-AR-2-2263</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>N01-AR1-2256</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI068759</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR056768</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR062886</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01-AR-4-4422</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01-AR056768</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01-AR057108</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01-AR059648</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2AR059092-01</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01-GM092691</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 May;44(5):483-9</RefSource>
                <PMID Version="1">22446960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 May;44(5):511-6</RefSource>
                <PMID Version="1">22446963</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2012 Mar 31;379(9822):1214-24</RefSource>
                <PMID Version="1">22421340</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Immunol. 2006 Dec;36(12):3305-14</RefSource>
                <PMID Version="1">17111354</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Jul;39(7):906-13</RefSource>
                <PMID Version="1">17572673</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 Sep;81(3):559-75</RefSource>
                <PMID Version="1">17701901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2008 Oct;9(10):1091-4</RefSource>
                <PMID Version="1">18800157</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2008 Oct 15;17(R2):R122-8</RefSource>
                <PMID Version="1">18852200</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6256-61</RefSource>
                <PMID Version="1">19329491</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Jun;42(6):508-14</RefSource>
                <PMID Version="1">20453842</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 2011 Feb;70(2):259-65</RefSource>
                <PMID Version="1">21156761</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2005 Mar 17;434(7031):400-4</RefSource>
                <PMID Version="1">15772666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2012 Mar 31;379(9822):1205-13</RefSource>
                <PMID Version="1">22421339</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2012 Mar 9;90(3):524-32</RefSource>
                <PMID Version="1">22365150</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):291-6</RefSource>
                <PMID Version="1">22286218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2012 Feb;9(2):179-81</RefSource>
                <PMID Version="1">22138821</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Dec;43(12):1193-201</RefSource>
                <PMID Version="1">22057235</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2011 Oct 7;89(4):496-506</RefSource>
                <PMID Version="1">21963258</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2011 Sep 10;378(9795):1006-14</RefSource>
                <PMID Version="1">21907864</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011 Aug;7(8):e1002197</RefSource>
                <PMID Version="1">21829388</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011 Feb;7(2):e1002004</RefSource>
                <PMID Version="1">21383967</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2003 Aug;34(4):395-402</RefSource>
                <PMID Version="1">12833157</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Rheumatol. 2013 Jan;9(1):4</RefSource>
                <PMID Version="1">23208187</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001172">Arthritis, Rheumatoid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001323">Autoantibodies</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002874">Chromosome Mapping</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044465">European Continental Ancestry Group</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D056426">Genetic Loci</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055106">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">EMS50373</OtherID>
        <OtherID Source="NLM">PMC3605761</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Barton</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Isaacs</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morgan</LastName>
                <ForeName>Ann</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilson</LastName>
                <ForeName>Gerry</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hyrich</LastName>
                <ForeName>Kimme</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moitra</LastName>
                <ForeName>R K</ForeName>
                <Initials>RK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prouse</LastName>
                <ForeName>P J</ForeName>
                <Initials>PJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shawe</LastName>
                <ForeName>D J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crisp</LastName>
                <ForeName>A J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gaston</LastName>
                <ForeName>J S H</ForeName>
                <Initials>JS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hall</LastName>
                <ForeName>F C</ForeName>
                <Initials>FC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hazleman</LastName>
                <ForeName>B L</ForeName>
                <Initials>BL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jenner</LastName>
                <ForeName>J R</ForeName>
                <Initials>JR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lillicrap</LastName>
                <ForeName>M S</ForeName>
                <Initials>MS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ostor</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Silverman</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Speed</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bruce</LastName>
                <ForeName>I N</ForeName>
                <Initials>IN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hyrich</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ho</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gorodkin</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Armstrong</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chuck</LastName>
                <ForeName>A J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hailwood</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kumar</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Badcock</LastName>
                <ForeName>L J</ForeName>
                <Initials>LJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Deighton</LastName>
                <ForeName>C M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Reilly</LastName>
                <ForeName>S C</ForeName>
                <Initials>SC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Raj</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Regan</LastName>
                <ForeName>M R</ForeName>
                <Initials>MR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Summers</LastName>
                <ForeName>G D</ForeName>
                <Initials>GD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Williams</LastName>
                <ForeName>R A</ForeName>
                <Initials>RA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lambert</LastName>
                <ForeName>J R</ForeName>
                <Initials>JR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stevens</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilkinson</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hamilton</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heycock</LastName>
                <ForeName>C R</ForeName>
                <Initials>CR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kelly</LastName>
                <ForeName>C A</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Saravanan</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rees</LastName>
                <ForeName>D H</ForeName>
                <Initials>DH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Williams</LastName>
                <ForeName>R B</ForeName>
                <Initials>RB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bingham</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Emery</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morgan</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bird</LastName>
                <ForeName>H A</ForeName>
                <Initials>HA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Conaghan</LastName>
                <ForeName>P G</ForeName>
                <Initials>PG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pease</LastName>
                <ForeName>C T</ForeName>
                <Initials>CT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wakefield</LastName>
                <ForeName>R J</ForeName>
                <Initials>RJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chalam</LastName>
                <ForeName>S V</ForeName>
                <Initials>SV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mulherin</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Price</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheeran</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Venkatachalam</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gaffney</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Macgregor</LastName>
                <ForeName>A J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marshall</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Merry</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scott</LastName>
                <ForeName>D G I</ForeName>
                <Initials>DG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Birrell</LastName>
                <ForeName>F N</ForeName>
                <Initials>FN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crook</LastName>
                <ForeName>P R</ForeName>
                <Initials>PR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harrison</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pattrick</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Snowden</LastName>
                <ForeName>H N</ForeName>
                <Initials>HN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bowden</LastName>
                <ForeName>A P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Smith</LastName>
                <ForeName>E E</ForeName>
                <Initials>EE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klimiuk</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Speden</LastName>
                <ForeName>D J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheehan</LastName>
                <ForeName>N J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Williams</LastName>
                <ForeName>N E</ForeName>
                <Initials>NE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dahiya</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hull</LastName>
                <ForeName>R G</ForeName>
                <Initials>RG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ledingham</LastName>
                <ForeName>J M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mccrae</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shaban</LastName>
                <ForeName>M R</ForeName>
                <Initials>MR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thomas</LastName>
                <ForeName>A L</ForeName>
                <Initials>AL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Young Min</LastName>
                <ForeName>S A</ForeName>
                <Initials>SA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bamji</LastName>
                <ForeName>A N</ForeName>
                <Initials>AN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cheung</LastName>
                <ForeName>N T</ForeName>
                <Initials>NT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Buckley</LastName>
                <ForeName>C D</ForeName>
                <Initials>CD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carruthers</LastName>
                <ForeName>D C</ForeName>
                <Initials>DC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Elamanchi</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>P C</ForeName>
                <Initials>PC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grindulis</LastName>
                <ForeName>K A</ForeName>
                <Initials>KA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Khattak</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Raza</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Situnayake</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Till</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Akil</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tattersall</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kilding</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dunley</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boulton</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tait</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilson</LastName>
                <ForeName>A G</ForeName>
                <Initials>AG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bax</LastName>
                <ForeName>D E</ForeName>
                <Initials>DE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clarke</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fordham</LastName>
                <ForeName>J N</ForeName>
                <Initials>JN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Plant</LastName>
                <ForeName>M J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tuck</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pathare</LastName>
                <ForeName>S K</ForeName>
                <Initials>SK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Edwards</LastName>
                <ForeName>C J</ForeName>
                <Initials>CJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Arden</LastName>
                <ForeName>N K</ForeName>
                <Initials>NK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Armstrong</LastName>
                <ForeName>R D</ForeName>
                <Initials>RD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Calogeras</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cooper</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Davidson</LastName>
                <ForeName>B K S</ForeName>
                <Initials>BK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dennison</LastName>
                <ForeName>E M</ForeName>
                <Initials>EM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abernethy</LastName>
                <ForeName>V E</ForeName>
                <Initials>VE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clewes</LastName>
                <ForeName>A R</ForeName>
                <Initials>AR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dawson</LastName>
                <ForeName>J K</ForeName>
                <Initials>JK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lynch</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kitas</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Delamere</LastName>
                <ForeName>J P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Erb</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klocke</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Whallett</LastName>
                <ForeName>A J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crook</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Foster</LastName>
                <ForeName>H E</ForeName>
                <Initials>HE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Griffiths</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Griffiths</LastName>
                <ForeName>I D</ForeName>
                <Initials>ID</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grove</LastName>
                <ForeName>M L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Isaacs</LastName>
                <ForeName>J D</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kay</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ng</LastName>
                <ForeName>W F</ForeName>
                <Initials>WF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Myers</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Platt</LastName>
                <ForeName>P N</ForeName>
                <Initials>PN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walker</LastName>
                <ForeName>D J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bowman</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jobanputra</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jubb</LastName>
                <ForeName>R W</ForeName>
                <Initials>RW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rankin</LastName>
                <ForeName>E C</ForeName>
                <Initials>EC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dawes</LastName>
                <ForeName>P T</ForeName>
                <Initials>PT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dowson</LastName>
                <ForeName>C M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hassell</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hay</LastName>
                <ForeName>E M</ForeName>
                <Initials>EM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kamath</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Packham</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sandhu</LastName>
                <ForeName>R S</ForeName>
                <Initials>RS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shadforth</LastName>
                <ForeName>M F</ForeName>
                <Initials>MF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bukhari</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dodds</LastName>
                <ForeName>W N</ForeName>
                <Initials>WN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Halsey</LastName>
                <ForeName>J P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mitchell</LastName>
                <ForeName>W S</ForeName>
                <Initials>WS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Reilly</LastName>
                <ForeName>D T</ForeName>
                <Initials>DT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>S P</ForeName>
                <Initials>SP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Doyle</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hakim</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lanham</LastName>
                <ForeName>J G</ForeName>
                <Initials>JG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tahir</LastName>
                <ForeName>H I S</ForeName>
                <Initials>HI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rathi</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rai</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rowe</LastName>
                <ForeName>I F</ForeName>
                <Initials>IF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prabu</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Buckley</LastName>
                <ForeName>C A M</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burton</LastName>
                <ForeName>Paul R</ForeName>
                <Initials>PR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clayton</LastName>
                <ForeName>David G</ForeName>
                <Initials>DG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cardon</LastName>
                <ForeName>Lon R</ForeName>
                <Initials>LR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Craddock</LastName>
                <ForeName>Nick</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Deloukas</LastName>
                <ForeName>Panos</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Duncanson</LastName>
                <ForeName>Audrey</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kwiatkowski</LastName>
                <ForeName>Dominic P</ForeName>
                <Initials>DP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McCarthy</LastName>
                <ForeName>Mark I</ForeName>
                <Initials>MI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ouwehand</LastName>
                <ForeName>Willem H</ForeName>
                <Initials>WH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Samani</LastName>
                <ForeName>Nilesh J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Todd</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barrett</LastName>
                <ForeName>Jeffrey C</ForeName>
                <Initials>JC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burton</LastName>
                <ForeName>Paul R</ForeName>
                <Initials>PR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Davison</LastName>
                <ForeName>Dan</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Easton</LastName>
                <ForeName>Doug</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Evans</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leung</LastName>
                <ForeName>Hin-Tak</ForeName>
                <Initials>HT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marchini</LastName>
                <ForeName>Jonathan L</ForeName>
                <Initials>JL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morris</LastName>
                <ForeName>Andrew P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spencer</LastName>
                <ForeName>Chris C A</ForeName>
                <Initials>CC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tobin</LastName>
                <ForeName>Martin D</ForeName>
                <Initials>MD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cardon</LastName>
                <ForeName>Lon R</ForeName>
                <Initials>LR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clayton</LastName>
                <ForeName>David G</ForeName>
                <Initials>DG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Attwood</LastName>
                <ForeName>Antony P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boorman</LastName>
                <ForeName>James P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cant</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Everson</LastName>
                <ForeName>Ursula</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hussey</LastName>
                <ForeName>Judith M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jolley</LastName>
                <ForeName>Jennifer D</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Knight</LastName>
                <ForeName>Alexandra S</ForeName>
                <Initials>AS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Koch</LastName>
                <ForeName>Kerstin</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meech</LastName>
                <ForeName>Elizabeth</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nutland</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prowse</LastName>
                <ForeName>Christopher V</ForeName>
                <Initials>CV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stevens</LastName>
                <ForeName>Helen E</ForeName>
                <Initials>HE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taylor</LastName>
                <ForeName>Niall C</ForeName>
                <Initials>NC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walters</LastName>
                <ForeName>Graham R</ForeName>
                <Initials>GR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walker</LastName>
                <ForeName>Neil M</ForeName>
                <Initials>NM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Watkins</LastName>
                <ForeName>Nicholas A</ForeName>
                <Initials>NA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Winzer</LastName>
                <ForeName>Thilo</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Todd</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ouwehand</LastName>
                <ForeName>Willem H</ForeName>
                <Initials>WH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jones</LastName>
                <ForeName>Richard W</ForeName>
                <Initials>RW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McArdle</LastName>
                <ForeName>Wendy L</ForeName>
                <Initials>WL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ring</LastName>
                <ForeName>Susan M</ForeName>
                <Initials>SM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Strachan</LastName>
                <ForeName>David P</ForeName>
                <Initials>DP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pembrey</LastName>
                <ForeName>Marcus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Breen</LastName>
                <ForeName>Gerome</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>St Clair</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caesar</LastName>
                <ForeName>Sian</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon-Smith</LastName>
                <ForeName>Katherine</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jones</LastName>
                <ForeName>Lisa</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fraser</LastName>
                <ForeName>Christine</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Green</LastName>
                <ForeName>Elaine K</ForeName>
                <Initials>EK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grozeva</LastName>
                <ForeName>Detelina</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hamshere</LastName>
                <ForeName>Marian L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Holmans</LastName>
                <ForeName>Peter A</ForeName>
                <Initials>PA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jones</LastName>
                <ForeName>Ian R</ForeName>
                <Initials>IR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kirov</LastName>
                <ForeName>George</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moskvina</LastName>
                <ForeName>Valentina</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nikolov</LastName>
                <ForeName>Ivan</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Donovan</LastName>
                <ForeName>Michael C</ForeName>
                <Initials>MC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Owen</LastName>
                <ForeName>Michael J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Craddock</LastName>
                <ForeName>Nick</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Collier</LastName>
                <ForeName>David A</ForeName>
                <Initials>DA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Elkin</LastName>
                <ForeName>Amanda</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Farmer</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Williamson</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McGuffin</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Young</LastName>
                <ForeName>Allan H</ForeName>
                <Initials>AH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ferrier</LastName>
                <ForeName>I Nicol</ForeName>
                <Initials>IN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ball</LastName>
                <ForeName>Stephen G</ForeName>
                <Initials>SG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Balmforth</LastName>
                <ForeName>Anthony J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barrett</LastName>
                <ForeName>Jennifer H</ForeName>
                <Initials>JH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bishop</LastName>
                <ForeName>D Timothy</ForeName>
                <Initials>DT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Iles</LastName>
                <ForeName>Mark M</ForeName>
                <Initials>MM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maqbool</LastName>
                <ForeName>Azhar</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yuldasheva</LastName>
                <ForeName>Nadira</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hall</LastName>
                <ForeName>Alistair S</ForeName>
                <Initials>AS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Braund</LastName>
                <ForeName>Peter S</ForeName>
                <Initials>PS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burton</LastName>
                <ForeName>Paul R</ForeName>
                <Initials>PR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dixon</LastName>
                <ForeName>Richard J</ForeName>
                <Initials>RJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mangino</LastName>
                <ForeName>Massimo</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stevens</LastName>
                <ForeName>Suzanne</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tobin</LastName>
                <ForeName>Martin D</ForeName>
                <Initials>MD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thompson</LastName>
                <ForeName>John R</ForeName>
                <Initials>JR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Samani</LastName>
                <ForeName>Nilesh J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bredin</LastName>
                <ForeName>Francesca</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tremelling</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Parkes</LastName>
                <ForeName>Miles</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Drummond</LastName>
                <ForeName>Hazel</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lees</LastName>
                <ForeName>Charles W</ForeName>
                <Initials>CW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nimmo</LastName>
                <ForeName>Elaine R</ForeName>
                <Initials>ER</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Satsangi</LastName>
                <ForeName>Jack</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fisher</LastName>
                <ForeName>Sheila A</ForeName>
                <Initials>SA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Forbes</LastName>
                <ForeName>Alastair</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lewis</LastName>
                <ForeName>Cathryn M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Onnie</LastName>
                <ForeName>Clive M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prescott</LastName>
                <ForeName>Natalie J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanderson</LastName>
                <ForeName>Jeremy</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathew</LastName>
                <ForeName>Christopher G</ForeName>
                <Initials>CG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barbour</LastName>
                <ForeName>Jamie</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mohiuddin</LastName>
                <ForeName>M Khalid</ForeName>
                <Initials>MK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Todhunter</LastName>
                <ForeName>Catherine E</ForeName>
                <Initials>CE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mansfield</LastName>
                <ForeName>John C</ForeName>
                <Initials>JC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ahmad</LastName>
                <ForeName>Tariq</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cummings</LastName>
                <ForeName>Fraser R</ForeName>
                <Initials>FR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jewell</LastName>
                <ForeName>Derek P</ForeName>
                <Initials>DP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Webster</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Morris J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clayton</LastName>
                <ForeName>David G</ForeName>
                <Initials>DG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lathrop</LastName>
                <ForeName>G Mark</ForeName>
                <Initials>GM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Connell</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dominiczak</LastName>
                <ForeName>Anna</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Samani</LastName>
                <ForeName>Nilesh J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Braga Marcano</LastName>
                <ForeName>Carolina A</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burke</LastName>
                <ForeName>Beverley</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dobson</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gungadoo</LastName>
                <ForeName>Johannie</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lee</LastName>
                <ForeName>Kate L</ForeName>
                <Initials>KL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Munroe</LastName>
                <ForeName>Patricia B</ForeName>
                <Initials>PB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Newhouse</LastName>
                <ForeName>Stephen J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Onipinla</LastName>
                <ForeName>Abiodun</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wallace</LastName>
                <ForeName>Chris</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Xue</LastName>
                <ForeName>Mingzhan</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caulfield</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Farrall</LastName>
                <ForeName>Martin</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barton</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bruce</LastName>
                <ForeName>Ian N</ForeName>
                <Initials>IN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donovan</LastName>
                <ForeName>Hannah</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eyre</LastName>
                <ForeName>Steve</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gilbert</LastName>
                <ForeName>Paul D</ForeName>
                <Initials>PD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hider</LastName>
                <ForeName>Samantha L</ForeName>
                <Initials>SL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hinks</LastName>
                <ForeName>Anne M</ForeName>
                <Initials>AM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>John</LastName>
                <ForeName>Sally L</ForeName>
                <Initials>SL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Potter</LastName>
                <ForeName>Catherine</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Silman</LastName>
                <ForeName>Alan J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Symmons</LastName>
                <ForeName>Deborah P M</ForeName>
                <Initials>DP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thomson</LastName>
                <ForeName>Wendy</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Worthington</LastName>
                <ForeName>Jane</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clayton</LastName>
                <ForeName>David G</ForeName>
                <Initials>DG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dunger</LastName>
                <ForeName>David B</ForeName>
                <Initials>DB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nutland</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stevens</LastName>
                <ForeName>Helen E</ForeName>
                <Initials>HE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walker</LastName>
                <ForeName>Neil M</ForeName>
                <Initials>NM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Widmer</LastName>
                <ForeName>Barry</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Todd</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Frayling</LastName>
                <ForeName>Timothy M</ForeName>
                <Initials>TM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Freathy</LastName>
                <ForeName>Rachel M</ForeName>
                <Initials>RM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lango</LastName>
                <ForeName>Hana</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perry</LastName>
                <ForeName>John R B</ForeName>
                <Initials>JR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shields</LastName>
                <ForeName>Beverley M</ForeName>
                <Initials>BM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weedon</LastName>
                <ForeName>Michael N</ForeName>
                <Initials>MN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hattersley</LastName>
                <ForeName>Andrew T</ForeName>
                <Initials>AT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hitman</LastName>
                <ForeName>Graham A</ForeName>
                <Initials>GA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walker</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Elliott</LastName>
                <ForeName>Kate S</ForeName>
                <Initials>KS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Groves</LastName>
                <ForeName>Christopher J</ForeName>
                <Initials>CJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lindgren</LastName>
                <ForeName>Cecilia M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rayner</LastName>
                <ForeName>Nigel W</ForeName>
                <Initials>NW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Timpson</LastName>
                <ForeName>Nicholas J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zeggini</LastName>
                <ForeName>Eleftheria</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McCarthy</LastName>
                <ForeName>Mark I</ForeName>
                <Initials>MI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Newport</LastName>
                <ForeName>Melanie</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sirugo</LastName>
                <ForeName>Giorgio</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lyons</LastName>
                <ForeName>Emily</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vannberg</LastName>
                <ForeName>Fredrik</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hill</LastName>
                <ForeName>Adrian V S</ForeName>
                <Initials>AV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bradbury</LastName>
                <ForeName>Linda A</ForeName>
                <Initials>LA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Farrar</LastName>
                <ForeName>Claire</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pointon</LastName>
                <ForeName>Jennifer J</ForeName>
                <Initials>JJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wordsworth</LastName>
                <ForeName>Paul</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Matthew A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Franklyn</LastName>
                <ForeName>Jayne A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heward</LastName>
                <ForeName>Joanne M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Simmonds</LastName>
                <ForeName>Matthew J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gough</LastName>
                <ForeName>Stephen C L</ForeName>
                <Initials>SC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seal</LastName>
                <ForeName>Sheila</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stratton</LastName>
                <ForeName>Michael R</ForeName>
                <Initials>MR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rahman</LastName>
                <ForeName>Nazneen</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ban</LastName>
                <ForeName>Maria</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goris</LastName>
                <ForeName>An</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sawcer</LastName>
                <ForeName>Stephen J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Compston</LastName>
                <ForeName>Alastair</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Conway</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jallow</LastName>
                <ForeName>Muminatou</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Newport</LastName>
                <ForeName>Melanie</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sirugo</LastName>
                <ForeName>Giorgio</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rockett</LastName>
                <ForeName>Kirk A</ForeName>
                <Initials>KA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kwiatkowski</LastName>
                <ForeName>Dominic P</ForeName>
                <Initials>DP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bumpstead</LastName>
                <ForeName>Suzannah J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chaney</LastName>
                <ForeName>Amy</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Downes</LastName>
                <ForeName>Kate</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ghori</LastName>
                <ForeName>Mohammed J R</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gwilliam</LastName>
                <ForeName>Rhian</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hunt</LastName>
                <ForeName>Sarah E</ForeName>
                <Initials>SE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Inouye</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Keniry</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>King</LastName>
                <ForeName>Emma</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McGinnis</LastName>
                <ForeName>Ralph</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Potter</LastName>
                <ForeName>Simon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ravindrarajah</LastName>
                <ForeName>Rathi</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Whittaker</LastName>
                <ForeName>Pamela</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Widden</LastName>
                <ForeName>Claire</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Withers</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Deloukas</LastName>
                <ForeName>Panos</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leung</LastName>
                <ForeName>Hin-Tak</ForeName>
                <Initials>HT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nutland</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stevens</LastName>
                <ForeName>Helen E</ForeName>
                <Initials>HE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walker</LastName>
                <ForeName>Neil M</ForeName>
                <Initials>NM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Todd</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Easton</LastName>
                <ForeName>Doug</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clayton</LastName>
                <ForeName>David G</ForeName>
                <Initials>DG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burton</LastName>
                <ForeName>Paul R</ForeName>
                <Initials>PR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tobin</LastName>
                <ForeName>Martin D</ForeName>
                <Initials>MD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barrett</LastName>
                <ForeName>Jeffrey C</ForeName>
                <Initials>JC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Evans</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morris</LastName>
                <ForeName>Andrew P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cardon</LastName>
                <ForeName>Lon R</ForeName>
                <Initials>LR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cardin</LastName>
                <ForeName>Niall J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Davison</LastName>
                <ForeName>Dan</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ferreira</LastName>
                <ForeName>Teresa</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pereira-Gale</LastName>
                <ForeName>Joanne</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hallgrimsdóttir</LastName>
                <ForeName>Ingileif B</ForeName>
                <Initials>IB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Howie</LastName>
                <ForeName>Bryan N</ForeName>
                <Initials>BN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marchini</LastName>
                <ForeName>Jonathan L</ForeName>
                <Initials>JL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spencer</LastName>
                <ForeName>Chris C A</ForeName>
                <Initials>CC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Su</LastName>
                <ForeName>Zhan</ForeName>
                <Initials>Z</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Teo</LastName>
                <ForeName>Yik Ying</ForeName>
                <Initials>YY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vukcevic</LastName>
                <ForeName>Damjan</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bentley</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Matthew A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cardon</LastName>
                <ForeName>Lon R</ForeName>
                <Initials>LR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caulfield</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Clayton</LastName>
                <ForeName>David G</ForeName>
                <Initials>DG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Compston</LastName>
                <ForeName>Alistair</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Craddock</LastName>
                <ForeName>Nick</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Deloukas</LastName>
                <ForeName>Panos</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Farrall</LastName>
                <ForeName>Martin</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gough</LastName>
                <ForeName>Stephen C L</ForeName>
                <Initials>SC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hall</LastName>
                <ForeName>Alistair S</ForeName>
                <Initials>AS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hattersley</LastName>
                <ForeName>Andrew T</ForeName>
                <Initials>AT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hill</LastName>
                <ForeName>Adrian V S</ForeName>
                <Initials>AV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kwiatkowski</LastName>
                <ForeName>Dominic P</ForeName>
                <Initials>DP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathew</LastName>
                <ForeName>Christopher G</ForeName>
                <Initials>CG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McCarthy</LastName>
                <ForeName>Mark I</ForeName>
                <Initials>MI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ouwehand</LastName>
                <ForeName>Willem H</ForeName>
                <Initials>WH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Parkes</LastName>
                <ForeName>Miles</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pembrey</LastName>
                <ForeName>Marcus</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rahman</LastName>
                <ForeName>Nazneen</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Samani</LastName>
                <ForeName>Nilesh J</ForeName>
                <Initials>NJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stratton</LastName>
                <ForeName>Michael R</ForeName>
                <Initials>MR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Todd</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Worthington</LastName>
                <ForeName>Jane</ForeName>
                <Initials>J</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2462</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2462</ArticleId>
            <ArticleId IdType="pubmed">23143596</ArticleId>
            <ArticleId IdType="pmc">PMC3605761</ArticleId>
            <ArticleId IdType="mid">EMS50373</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23143594</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1341-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2467</ELocationID>
            <Abstract>
                <AbstractText>To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. We identified 15 new susceptibility loci, increasing to 36 the number associated with psoriasis in European individuals. We also identified, using conditional analyses, five independent signals within previously known loci. The newly identified loci shared with other autoimmune diseases include candidate genes with roles in regulating T-cell function (such as RUNX3, TAGAP and STAT3). Notably, they included candidate genes whose products are involved in innate host defense, including interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C) and nuclear factor (NF)-κB signaling (CARD14 and CARM1). These results portend a better understanding of shared and distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the importance of the skin in innate and acquired host defense.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tsoi</LastName>
                    <ForeName>Lam C</ForeName>
                    <Initials>LC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Center for Statistical Genetics, University of Michigan Ann Arbor, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spain</LastName>
                    <ForeName>Sarah L</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knight</LastName>
                    <ForeName>Jo</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ellinghaus</LastName>
                    <ForeName>Eva</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stuart</LastName>
                    <ForeName>Philip E</ForeName>
                    <Initials>PE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Capon</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yanming</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tejasvi</LastName>
                    <ForeName>Trilokraj</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gudjonsson</LastName>
                    <ForeName>Johann E</ForeName>
                    <Initials>JE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Hyun M</ForeName>
                    <Initials>HM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allen</LastName>
                    <ForeName>Michael H</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McManus</LastName>
                    <ForeName>Ross</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Novelli</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samuelsson</LastName>
                    <ForeName>Lena</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schalkwijk</LastName>
                    <ForeName>Joost</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ståhle</LastName>
                    <ForeName>Mona</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burden</LastName>
                    <ForeName>A David</ForeName>
                    <Initials>AD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Catherine H</ForeName>
                    <Initials>CH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cork</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Estivill</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowcock</LastName>
                    <ForeName>Anne M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krueger</LastName>
                    <ForeName>Gerald G</ForeName>
                    <Initials>GG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weger</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Worthington</LastName>
                    <ForeName>Jane</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tazi-Ahnini</LastName>
                    <ForeName>Rachid</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nestle</LastName>
                    <ForeName>Frank O</ForeName>
                    <Initials>FO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayday</LastName>
                    <ForeName>Adrian</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffmann</LastName>
                    <ForeName>Per</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winkelmann</LastName>
                    <ForeName>Juliane</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wijmenga</LastName>
                    <ForeName>Cisca</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langford</LastName>
                    <ForeName>Cordelia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Edkins</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andrews</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blackburn</LastName>
                    <ForeName>Hannah</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strange</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Band</LastName>
                    <ForeName>Gavin</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pearson</LastName>
                    <ForeName>Richard D</ForeName>
                    <Initials>RD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vukcevic</LastName>
                    <ForeName>Damjan</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spencer</LastName>
                    <ForeName>Chris C A</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deloukas</LastName>
                    <ForeName>Panos</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mrowietz</LastName>
                    <ForeName>Ulrich</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schreiber</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weidinger</LastName>
                    <ForeName>Stephan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koks</LastName>
                    <ForeName>Sulev</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kingo</LastName>
                    <ForeName>Külli</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Esko</LastName>
                    <ForeName>Tonu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Metspalu</LastName>
                    <ForeName>Andres</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Henry W</ForeName>
                    <Initials>HW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voorhees</LastName>
                    <ForeName>John J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weichenthal</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wichmann</LastName>
                    <ForeName>H Erich</ForeName>
                    <Initials>HE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chandran</LastName>
                    <ForeName>Vinod</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosen</LastName>
                    <ForeName>Cheryl F</ForeName>
                    <Initials>CF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rahman</LastName>
                    <ForeName>Proton</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gladman</LastName>
                    <ForeName>Dafna D</ForeName>
                    <Initials>DD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Griffiths</LastName>
                    <ForeName>Christopher E M</ForeName>
                    <Initials>CE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reis</LastName>
                    <ForeName>Andre</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kere</LastName>
                    <ForeName>Juha</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Collaborative Association Study of Psoriasis (CASP)</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Genetic Analysis of Psoriasis Consortium</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Psoriasis Association Genetics Extension</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Wellcome Trust Case Control Consortium 2</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nair</LastName>
                    <ForeName>Rajan P</ForeName>
                    <Initials>RP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franke</LastName>
                    <ForeName>Andre</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barker</LastName>
                    <ForeName>Jonathan N W N</ForeName>
                    <Initials>JN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abecasis</LastName>
                    <ForeName>Goncalo R</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elder</LastName>
                    <ForeName>James T</ForeName>
                    <Initials>JT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trembath</LastName>
                    <ForeName>Richard C</ForeName>
                    <Initials>RC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>068545/Z/02</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>083948/Z/07/Z</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>085475/B/08/Z</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>085780</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>090532</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>098439</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>17552</GrantID>
                    <Agency>Arthritis Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>AR054966</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>G0000934</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0601387</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G060I1387</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0700314</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>HG007022</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K08 AR057763</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K08 AR060802</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/J006742/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR042742</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR042742</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR050266</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR050266</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR050511</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR050511</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR054966</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC1 AR058315</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053468">CARD Signaling Adaptor Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050677">Core Binding Factor Alpha 3 Subunit</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C493729">Runx3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C557017">TAGAP protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="C452820">DDX58 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.13</RegistryNumber>
                <NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.6.1.-</RegistryNumber>
                <NameOfSubstance UI="C426243">CARD14 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.6.1.2</RegistryNumber>
                <NameOfSubstance UI="C426242">CARD11 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.6.1.2</RegistryNumber>
                <NameOfSubstance UI="D006162">Guanylate Cyclase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2009 Jun;5(6):e1000529</RefSource>
                <PMID Version="1">19543373</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2009 Jul 30;361(5):496-509</RefSource>
                <PMID Version="1">19641206</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2009 Aug;5(8):e1000606</RefSource>
                <PMID Version="1">19680446</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dtsch Dermatol Ges. 2009 Oct;7(10):862-9</RefSource>
                <PMID Version="1">19725839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2009 Nov 23;206(12):2685-99</RefSource>
                <PMID Version="1">19917777</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Feb 18;463(7283):953-7</RefSource>
                <PMID Version="1">20164929</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Apr;42(4):295-302</RefSource>
                <PMID Version="1">20190752</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Apr;42(4):348-54</RefSource>
                <PMID Version="1">20208533</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2010 Apr 12;207(4):721-30</RefSource>
                <PMID Version="1">20231379</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2012 Mar;132(3 Pt 2):882-6</RefSource>
                <PMID Version="1">22158552</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2012 Mar;132(3 Pt 2):887-95</RefSource>
                <PMID Version="1">22158560</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2012 Mar;132(3 Pt 2):915-22</RefSource>
                <PMID Version="1">22158561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2012 Apr 6;90(4):636-47</RefSource>
                <PMID Version="1">22482804</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2012 May 4;90(5):784-95</RefSource>
                <PMID Version="1">22521418</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2012 May 4;90(5):796-808</RefSource>
                <PMID Version="1">22521419</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):955-9</RefSource>
                <PMID Version="1">22820512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2010 May;130(5):1213-26</RefSource>
                <PMID Version="1">19812592</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2010 Jul;130(7):1829-40</RefSource>
                <PMID Version="1">20220767</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2010 Sep;120(9):3280-95</RefSource>
                <PMID Version="1">20697158</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Sep 2;467(7311):52-8</RefSource>
                <PMID Version="1">20811451</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Enzymol. 2010;479:185-204</RefSource>
                <PMID Version="1">20816167</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2010 Sep;6(9):e1001113</RefSource>
                <PMID Version="1">20844574</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Sci. 2010 Oct 15;123(Pt 20):3566-75</RefSource>
                <PMID Version="1">20930145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2010 Oct;6(10):e1001157</RefSource>
                <PMID Version="1">20976248</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Nov;42(11):1005-9</RefSource>
                <PMID Version="1">20953187</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Nov;42(11):991-5</RefSource>
                <PMID Version="1">20953188</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Nov;42(11):1000-4</RefSource>
                <PMID Version="1">20953189</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Nov;42(11):985-90</RefSource>
                <PMID Version="1">20953190</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Oct 28;467(7319):1061-73</RefSource>
                <PMID Version="1">20981092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2010 Dec 10;87(6):779-89</RefSource>
                <PMID Version="1">21129726</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Dec;42(12):1118-25</RefSource>
                <PMID Version="1">21102463</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Res. 2011 Jan;21(1):55-70</RefSource>
                <PMID Version="1">21187856</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dermatol Sci. 2011 Feb;61(2):124-8</RefSource>
                <PMID Version="1">21208785</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Genomics. 2011;12:98</RefSource>
                <PMID Version="1">21299892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2011;6(2):e17160</RefSource>
                <PMID Version="1">21364948</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011 Feb;7(2):e1002004</RefSource>
                <PMID Version="1">21383967</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2011 May;131(5):1105-9</RefSource>
                <PMID Version="1">21107349</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Inflamm Bowel Dis. 2011 Jun;17(6):1343-58</RefSource>
                <PMID Version="1">21305677</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunity. 2011 May 27;34(5):680-92</RefSource>
                <PMID Version="1">21616437</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2011 Jul;29(7):563-6</RefSource>
                <PMID Version="1">21747375</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011 Aug;7(8):e1002254</RefSource>
                <PMID Version="1">21852963</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2011 Oct;131(10):2010-6</RefSource>
                <PMID Version="1">21654830</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2011 Oct;12(10):1010-6</RefSource>
                <PMID Version="1">21892172</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2011 Sep 30;286(39):33811-8</RefSource>
                <PMID Version="1">21757742</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Res Ther. 2011;13(1):101</RefSource>
                <PMID Version="1">21345260</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Dec;43(12):1193-201</RefSource>
                <PMID Version="1">22057235</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gene. 2012 Feb 10;493(2):211-8</RefSource>
                <PMID Version="1">22178530</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 2000 Mar 1;64(2):195-202</RefSource>
                <PMID Version="1">10729226</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biometrics. 1999 Dec;55(4):997-1004</RefSource>
                <PMID Version="1">11315092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2001 Feb 2;276(5):3498-507</RefSource>
                <PMID Version="1">11042166</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2001 Aug 15;10(17):1793-805</RefSource>
                <PMID Version="1">11532989</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Oct 31;419(6910):944-7</RefSource>
                <PMID Version="1">12410315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Acad Dermatol. 2003 Jun;48(6):805-21; quiz 822-4</RefSource>
                <PMID Version="1">12789169</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2004 Apr;36(4):388-93</RefSource>
                <PMID Version="1">15052270</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Cell Biol. 2004 Jun;82(3):401-5</RefSource>
                <PMID Version="1">15181474</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1998 May 29;93(5):731-40</RefSource>
                <PMID Version="1">9630218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1998 Sep 1;92(5):1668-76</RefSource>
                <PMID Version="1">9716595</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2005 Jan;11(1):43-9</RefSource>
                <PMID Version="1">15592573</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gesundheitswesen. 2005 Aug;67 Suppl 1:S26-30</RefSource>
                <PMID Version="1">16032514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 Nov 18;280(46):38247-58</RefSource>
                <PMID Version="1">16169848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Alzheimer Res. 2005 Dec;2(5):559-69</RefSource>
                <PMID Version="1">16375659</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Biochem. 2006;7:9</RefSource>
                <PMID Version="1">16566820</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2006 May;12(5):568-73</RefSource>
                <PMID Version="1">16648858</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2006 Sep 15;177(6):3821-6</RefSource>
                <PMID Version="1">16951344</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18668-73</RefSource>
                <PMID Version="1">17130451</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2007 Feb;8(2):145-53</RefSource>
                <PMID Version="1">17195845</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Jul;39(7):906-13</RefSource>
                <PMID Version="1">17572673</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 Sep;81(3):559-75</RefSource>
                <PMID Version="1">17701901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2007 Oct 1;179(7):4313-7</RefSource>
                <PMID Version="1">17878325</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1337-43</RefSource>
                <PMID Version="1">17958839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2007 Nov 26;204(12):2825-35</RefSource>
                <PMID Version="1">17967903</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2008 Mar 7;283(10):6337-46</RefSource>
                <PMID Version="1">18178554</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2008 Mar 15;180(6):3746-56</RefSource>
                <PMID Version="1">18322180</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2008 Oct 1;24(19):2209-14</RefSource>
                <PMID Version="1">18653518</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Cell Dev Biol. 2008 Aug;19(4):394-400</RefSource>
                <PMID Version="1">18708155</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20446-51</RefSource>
                <PMID Version="1">19074283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20846-51</RefSource>
                <PMID Version="1">19088203</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Feb;41(2):211-5</RefSource>
                <PMID Version="1">19169253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Feb;41(2):199-204</RefSource>
                <PMID Version="1">19169254</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Feb;41(2):205-10</RefSource>
                <PMID Version="1">19169255</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053468">CARD Signaling Adaptor Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050677">Core Binding Factor Alpha 3 Subunit</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044465">European Continental Ancestry Group</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020690">GTPase-Activating Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D056426">Genetic Loci</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055106">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006162">Guanylate Cyclase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011565">Psoriasis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS416128</OtherID>
        <OtherID Source="NLM">PMC3510312</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Duffin</LastName>
                <ForeName>Kristina Callis</ForeName>
                <Initials>KC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Helms</LastName>
                <ForeName>Cindy</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goldgar</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Yun</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paschall</LastName>
                <ForeName>Justin</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Malloy</LastName>
                <ForeName>Mary J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pullinger</LastName>
                <ForeName>Clive R</ForeName>
                <Initials>CR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kane</LastName>
                <ForeName>John P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gardner</LastName>
                <ForeName>Jennifer</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perlmutter</LastName>
                <ForeName>Amy</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miner</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Feng</LastName>
                <ForeName>Bing Jian</ForeName>
                <Initials>BJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hiremagalore</LastName>
                <ForeName>Ravi</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ike</LastName>
                <ForeName>Robert W</ForeName>
                <Initials>RW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Christophers</LastName>
                <ForeName>Enno</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Henseler</LastName>
                <ForeName>Tilo</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruether</LastName>
                <ForeName>Andreas</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schrodi</LastName>
                <ForeName>Steven J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prahalad</LastName>
                <ForeName>Sampath</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Guthery</LastName>
                <ForeName>Stephen L</ForeName>
                <Initials>SL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fischer</LastName>
                <ForeName>Judith</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liao</LastName>
                <ForeName>Wilson</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kwok</LastName>
                <ForeName>Pui</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Menter</LastName>
                <ForeName>Alan</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lathrop</LastName>
                <ForeName>G Mark</ForeName>
                <Initials>GM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wise</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Begovich</LastName>
                <ForeName>Ann B</ForeName>
                <Initials>AB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Onoufriadis</LastName>
                <ForeName>Alexandros</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weale</LastName>
                <ForeName>Michael E</ForeName>
                <Initials>ME</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hofer</LastName>
                <ForeName>Angelika</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Salmhofer</LastName>
                <ForeName>Wolfgang</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wolf</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kainu</LastName>
                <ForeName>Kati</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Saarialho-Kere</LastName>
                <ForeName>Ulpu</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suomela</LastName>
                <ForeName>Sari</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Badorf</LastName>
                <ForeName>Petra</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hüffmeier</LastName>
                <ForeName>Ulrike</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kurrat</LastName>
                <ForeName>Werner</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Küster</LastName>
                <ForeName>Wolfgang</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lascorz</LastName>
                <ForeName>Jesús</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mössner</LastName>
                <ForeName>Rotraut</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schürmeier-Horst</LastName>
                <ForeName>Funda</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ständer</LastName>
                <ForeName>Markward</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Traupe</LastName>
                <ForeName>Heiko</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bergboer</LastName>
                <ForeName>Judith G M</ForeName>
                <Initials>JG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>den Heijer</LastName>
                <ForeName>Martin</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>van de Kerkhof</LastName>
                <ForeName>Peter C</ForeName>
                <Initials>PC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zeeuwen</LastName>
                <ForeName>Patrick L J M</ForeName>
                <Initials>PL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barnes</LastName>
                <ForeName>Louise</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Campbell</LastName>
                <ForeName>Linda E</ForeName>
                <Initials>LE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cusack</LastName>
                <ForeName>Caitriona</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Coleman</LastName>
                <ForeName>Ciara</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Conroy</LastName>
                <ForeName>Judith</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ennis</LastName>
                <ForeName>Sean</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fitzgerald</LastName>
                <ForeName>Oliver</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gallagher</LastName>
                <ForeName>Phil</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Irvine</LastName>
                <ForeName>Alan D</ForeName>
                <Initials>AD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kirby</LastName>
                <ForeName>Brian</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Markham</LastName>
                <ForeName>Trevor</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McLean</LastName>
                <ForeName>W H Irwin</ForeName>
                <Initials>WH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McPartlin</LastName>
                <ForeName>Joe</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rogers</LastName>
                <ForeName>Sarah F</ForeName>
                <Initials>SF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryan</LastName>
                <ForeName>Anthony W</ForeName>
                <Initials>AW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zawirska</LastName>
                <ForeName>Agnieszka</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Giardina</LastName>
                <ForeName>Emiliano</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lepre</LastName>
                <ForeName>Tiziana</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perricone</LastName>
                <ForeName>Carlo</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martín-Ezquerra</LastName>
                <ForeName>Gemma</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pujol</LastName>
                <ForeName>Ramon M</ForeName>
                <Initials>RM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Riveira-Munoz</LastName>
                <ForeName>Eva</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Inerot</LastName>
                <ForeName>Annica</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Naluai</LastName>
                <ForeName>Åsa T</ForeName>
                <Initials>ÅT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mallbris</LastName>
                <ForeName>Lotus</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wolk</LastName>
                <ForeName>Katarina</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leman</LastName>
                <ForeName>Joyce</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barton</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Warren</LastName>
                <ForeName>Richard B</ForeName>
                <Initials>RB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Young</LastName>
                <ForeName>Helen S</ForeName>
                <Initials>HS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ricano-Ponce</LastName>
                <ForeName>Isis</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trynka</LastName>
                <ForeName>Gosia</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pellett</LastName>
                <ForeName>Fawnda J</ForeName>
                <Initials>FJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Henschel</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aurand</LastName>
                <ForeName>Marin</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bebo</LastName>
                <ForeName>Bruce</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gieger</LastName>
                <ForeName>Christian</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Illig</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moebus</LastName>
                <ForeName>Susanne</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jöckel</LastName>
                <ForeName>Karl-Heinz</ForeName>
                <Initials>KH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Erbel</LastName>
                <ForeName>Raimund</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peltonen</LastName>
                <ForeName>Leena</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Blackwell</LastName>
                <ForeName>Jenefer M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bramon</LastName>
                <ForeName>Elvira</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Matthew A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Casas</LastName>
                <ForeName>Juan P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Corvin</LastName>
                <ForeName>Aiden</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Craddock</LastName>
                <ForeName>Nicholas</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Duncanson</LastName>
                <ForeName>Audrey</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jankowski</LastName>
                <ForeName>Janusz</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Markus</LastName>
                <ForeName>Hugh S</ForeName>
                <Initials>HS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathew</LastName>
                <ForeName>Christopher G</ForeName>
                <Initials>CG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McCarthy</LastName>
                <ForeName>Mark I</ForeName>
                <Initials>MI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Palmer</LastName>
                <ForeName>Colin N A</ForeName>
                <Initials>CN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Plomin</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rautanen</LastName>
                <ForeName>Anna</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sawcer</LastName>
                <ForeName>Stephen J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Samani</LastName>
                <ForeName>Nilesh</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Viswanathan</LastName>
                <ForeName>Ananth C</ForeName>
                <Initials>AC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wood</LastName>
                <ForeName>Nicholas W</ForeName>
                <Initials>NW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bellenguez</LastName>
                <ForeName>Céline</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Freeman</LastName>
                <ForeName>Colin</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hellenthal</LastName>
                <ForeName>Garrett</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Giannoulatou</LastName>
                <ForeName>Eleni</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pirinen</LastName>
                <ForeName>Matti</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Su</LastName>
                <ForeName>Zhan</ForeName>
                <Initials>Z</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hunt</LastName>
                <ForeName>Sarah E</ForeName>
                <Initials>SE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gwilliam</LastName>
                <ForeName>Rhian</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bumpstead</LastName>
                <ForeName>Suzannah J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dronov</LastName>
                <ForeName>Serge</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gillman</LastName>
                <ForeName>Matthew</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gray</LastName>
                <ForeName>Emma</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hammond</LastName>
                <ForeName>Naomi</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jayakumar</LastName>
                <ForeName>Alagurevathi</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McCann</LastName>
                <ForeName>Owen T</ForeName>
                <Initials>OT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liddle</LastName>
                <ForeName>Jennifer</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perez</LastName>
                <ForeName>Marc L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Potter</LastName>
                <ForeName>Simon C</ForeName>
                <Initials>SC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ravindrarajah</LastName>
                <ForeName>Radhi</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ricketts</LastName>
                <ForeName>Michelle</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Waller</LastName>
                <ForeName>Matthew</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weston</LastName>
                <ForeName>Paul</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Widaa</LastName>
                <ForeName>Sara</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Whittaker</LastName>
                <ForeName>Pamela</ForeName>
                <Initials>P</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2467</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2467</ArticleId>
            <ArticleId IdType="pubmed">23143594</ArticleId>
            <ArticleId IdType="pmc">PMC3510312</ArticleId>
            <ArticleId IdType="mid">NIHMS416128</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">702743</PMID>
        <DateCreated>
            <Year>1978</Year>
            <Month>12</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1978</Year>
            <Month>12</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0098-7484</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>240</Volume>
                    <Issue>21</Issue>
                    <PubDate>
                        <Year>1978</Year>
                        <Month>Nov</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA</Title>
                <ISOAbbreviation>JAMA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ventricular tachycardia after terbutaline.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2247</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kinney</LastName>
                    <ForeName>E L</ForeName>
                    <Initials>EL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trautlein</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harbaugh</LastName>
                    <ForeName>C V</ForeName>
                    <Initials>CV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lambert</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zelis</LastName>
                    <ForeName>R F</ForeName>
                    <Initials>RF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>JAMA</MedlineTA>
            <NlmUniqueID>7501160</NlmUniqueID>
            <ISSNLinking>0098-7484</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>N8ONU3L3PG</RegistryNumber>
                <NameOfSubstance UI="D013726">Terbutaline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003327">Coronary Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006352">Heart Ventricles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013610">Tachycardia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013726">Terbutaline</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1978</Year>
                <Month>11</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1978</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1978</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">702743</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10578133</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-1188</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>128</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of pharmacology</Title>
                <ISOAbbreviation>Br. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1207-14</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>1 The effect of S 15535 (4-benzodioxan-5-yl)1-(indan-2-yl)piperazine), an agonist at presynaptic and antagonist at postsynaptic 5-HT1A receptors, on the impairment of spatial learning caused by intrahippocampal scopolamine in a two-platform spatial discrimination task was studied. 2 Scopolamine (4.0 microg microl-1), injected bilaterally into the CA1 region of the dorsal hippocampus 10 min before each training session, impaired choice accuracy with no effect on choice latency and errors of omission. 3 Administered subcutaneously 30 min before each training session, S 15535 1.0 (but not 0.3) mg kg-1 did not modify choice accuracy but prevented its impairment by intrahippocampal scopolamine. 4 WAY 100635, a 5-HT1A receptor antagonist, injected into the dorsal raphe at 1.0 microg 0.5 microl-1 5 min before scopolamine, had no effect on choice accuracy and latency or errors of omission and did not modify the effect of scopolamine but completely antagonized the effect of S 15535 (1.0 mg kg-1) on scopolamine-induced impairment of choice accuracy. 5 The results confirm a previous report (Carli et al., 1998) that stimulation of presynaptic 5-HT1A receptors in the dorsal raphe counteracts the deficit caused by intrahippocampal scopolamine, probably by facilitating the transfer of facilitatory information from the entorhinal cortex to the hippocampus. 6 Drugs that stimulate action on presynaptic 5-HT1A receptors, such as S 15535 and other partial 5-HT1A receptors agonists, may be useful in the symptomatic treatment of human memory disturbances associated with loss of cholinergic innervation to the hippocampus.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Carli</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Neuropharmacology, Mario Negri Institute for Pharmacological Research, Via Eritrea 62,20157 Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balducci</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Millan</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonalumi</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samanin</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br J Pharmacol</MedlineTA>
            <NlmUniqueID>7502536</NlmUniqueID>
            <ISSNLinking>0007-1188</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044263">Receptors, Serotonin, 5-HT1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017366">Serotonin Receptor Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>146998-34-7</RegistryNumber>
                <NameOfSubstance UI="C079549">4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>451IFR0GXB</RegistryNumber>
                <NameOfSubstance UI="D012601">Scopolamine Hydrobromide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71IH826FEG</RegistryNumber>
                <NameOfSubstance UI="C090413">N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1974 Sep 27;78(2):320-6</RefSource>
                <PMID Version="1">4853717</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1998 Oct 5;807(1-2):187-92</RefSource>
                <PMID Version="1">9757032</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1982 Jun 24;297(5868):681-3</RefSource>
                <PMID Version="1">7088155</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1982 Aug 19;246(1):77-87</RefSource>
                <PMID Version="1">6289975</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Q J Exp Psychol B. 1986 Nov;38(4):365-95</RefSource>
                <PMID Version="1">3809580</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 1987 Apr;24(1):39-46</RefSource>
                <PMID Version="1">3580114</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1987 Jul 2-8;328(6125):73-7</RefSource>
                <PMID Version="1">3600775</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Naunyn Schmiedebergs Arch Pharmacol. 1987 Jul;336(1):5-10</RefSource>
                <PMID Version="1">2888027</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 1988 Jul;27(7):707-15</RefSource>
                <PMID Version="1">2901680</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 1988 Oct;27(10):993-1001</RefSource>
                <PMID Version="1">2467224</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurochem. 1991 Jan;56(1):243-7</RefSource>
                <PMID Version="1">1824782</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Physiol Rev. 1992 Jan;72(1):165-229</RefSource>
                <PMID Version="1">1731370</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Pharmacol. 1992 Mar;105(3):720-6</RefSource>
                <PMID Version="1">1385752</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1992 Nov 6;595(1):50-6</RefSource>
                <PMID Version="1">1467958</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 1993 Jan 5;230(1):99-102</RefSource>
                <PMID Version="1">8381359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurochem. 1993 May;60(5):1589-604</RefSource>
                <PMID Version="1">8473885</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1994 Jan;268(1):337-52</RefSource>
                <PMID Version="1">8301575</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 1994 Aug 31;63(2):187-94</RefSource>
                <PMID Version="1">7999302</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 1995 Feb;67(1):67-74</RefSource>
                <PMID Version="1">7748502</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurosci Lett. 1995 Apr 28;190(1):37-40</RefSource>
                <PMID Version="1">7624050</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Ther. 1995 Apr;66(1):103-48</RefSource>
                <PMID Version="1">7630926</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 1995 Jul 25;281(1):81-8</RefSource>
                <PMID Version="1">8566121</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 1995 Sep 5;283(1-3):133-9</RefSource>
                <PMID Version="1">7498302</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Pharmacol. 1995 Jul;115(6):1064-70</RefSource>
                <PMID Version="1">7582504</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1996 May 24;272(5265):1176-9</RefSource>
                <PMID Version="1">8638163</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Biochem Behav. 1996 May;54(1):143-7</RefSource>
                <PMID Version="1">8728551</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 1996 Oct;127(3):245-54</RefSource>
                <PMID Version="1">8912403</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res Bull. 1996;41(5):299-304</RefSource>
                <PMID Version="1">8924041</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 1997 Jan;82(2):185-94</RefSource>
                <PMID Version="1">9030400</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1997 Jul;282(1):148-61</RefSource>
                <PMID Version="1">9223550</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 1997 Apr-May;36(4-5):467-73</RefSource>
                <PMID Version="1">9225271</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res Bull. 1998;45(1):89-93</RefSource>
                <PMID Version="1">9434207</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1997 Nov 7;774(1-2):167-74</RefSource>
                <PMID Version="1">9452205</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Neurosci. 1998 Jan;10(1):221-30</RefSource>
                <PMID Version="1">9753130</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1981 Apr 27;211(1):227-34</RefSource>
                <PMID Version="1">7225840</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007859">Learning Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018782">Maze Learning</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011903">Raphe Nuclei</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011985">Receptors, Serotonin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044263">Receptors, Serotonin, 5-HT1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012601">Scopolamine Hydrobromide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012702">Serotonin Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017366">Serotonin Receptor Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013569">Synapses</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1571756</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10578133</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.bjp.0702915</ArticleId>
            <ArticleId IdType="pmc">PMC1571756</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">276660</PMID>
        <DateCreated>
            <Year>1978</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1978</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0028-7628</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>78</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>1978</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>New York state journal of medicine</Title>
                <ISOAbbreviation>N Y State J Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1239-43</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sternlieb</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robinson</LastName>
                    <ForeName>R M</ForeName>
                    <Initials>RM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>N Y State J Med</MedlineTA>
            <NlmUniqueID>0401064</NlmUniqueID>
            <ISSNLinking>0028-7628</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>WK2XYI10QM</RegistryNumber>
                <NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007052">Ibuprofen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013262">Stevens-Johnson Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1978</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1978</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1978</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">276660</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23143597</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The genetic landscape of mutations in Burkitt lymphoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1321-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2468</ELocationID>
            <Abstract>
                <AbstractText>Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other genetic mutations to the disease is largely unknown. Here, we describe the first completely sequenced genome from a Burkitt lymphoma tumor and germline DNA from the same affected individual. We further sequenced the exomes of 59 Burkitt lymphoma tumors and compared them to sequenced exomes from 94 diffuse large B-cell lymphoma (DLBCL) tumors. We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4. Our data implicate a number of genes in cancer for the first time, including CCT6B, SALL3, FTCD and PC. ID3 mutations occurred in 34% of Burkitt lymphomas and not in DLBCLs. We show experimentally that ID3 mutations promote cell cycle progression and proliferation. Our work thus elucidates commonly occurring gene-coding mutations in Burkitt lymphoma and implicates ID3 as a new tumor suppressor gene.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Love</LastName>
                    <ForeName>Cassandra</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Zhen</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jima</LastName>
                    <ForeName>Dereje</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Guojie</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jenny</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miles</LastName>
                    <ForeName>Rodney</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richards</LastName>
                    <ForeName>Kristy L</ForeName>
                    <Initials>KL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dunphy</LastName>
                    <ForeName>Cherie H</ForeName>
                    <Initials>CH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>William W L</ForeName>
                    <Initials>WW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Srivastava</LastName>
                    <ForeName>Gopesh</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lugar</LastName>
                    <ForeName>Patricia L</ForeName>
                    <Initials>PL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rizzieri</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lagoo</LastName>
                    <ForeName>Anand S</ForeName>
                    <Initials>AS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernal-Mizrachi</LastName>
                    <ForeName>Leon</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mann</LastName>
                    <ForeName>Karen P</ForeName>
                    <Initials>KP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flowers</LastName>
                    <ForeName>Christopher R</ForeName>
                    <Initials>CR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naresh</LastName>
                    <ForeName>Kikkeri N</ForeName>
                    <Initials>KN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Evens</LastName>
                    <ForeName>Andrew M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chadburn</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Leo I</ForeName>
                    <Initials>LI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Czader</LastName>
                    <ForeName>Magdalena B</ForeName>
                    <Initials>MB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gill</LastName>
                    <ForeName>Javed I</ForeName>
                    <Initials>JI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsi</LastName>
                    <ForeName>Eric D</ForeName>
                    <Initials>ED</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greenough</LastName>
                    <ForeName>Adrienne</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moffitt</LastName>
                    <ForeName>Andrea B</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McKinney</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Banerjee</LastName>
                    <ForeName>Anjishnu</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grubor</LastName>
                    <ForeName>Vladimir</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levy</LastName>
                    <ForeName>Shawn</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dunson</LastName>
                    <ForeName>David B</ForeName>
                    <Initials>DB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dave</LastName>
                    <ForeName>Sandeep S</ForeName>
                    <Initials>SS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GEO</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>GSE22898</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 ES017436</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA136895</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21CA1561686</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 GM007184</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C112476">ARID1A protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C533303">CCT6B protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051796">Inhibitor of Differentiation Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C521076">PIK3IP1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C484466">SALL3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>147785-34-0</RegistryNumber>
                <NameOfSubstance UI="C075640">ID3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.1.2.5</RegistryNumber>
                <NameOfSubstance UI="C494848">FTCD protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.1.2.5</RegistryNumber>
                <NameOfSubstance UI="D051042">Glutamate Formimidoyltransferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D051096">Proto-Oncogene Proteins c-ret</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C099282">RET protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D056404">Chaperonin Containing TCP-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="C084108">SMARCA4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.-</RegistryNumber>
                <NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.5.1</RegistryNumber>
                <NameOfSubstance UI="D044365">GTP-Binding Protein alpha Subunits, G12-G13</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.3.1.-</RegistryNumber>
                <NameOfSubstance UI="D000642">Ammonia-Lyases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mol Biol. 1970 Mar;48(3):443-53</RefSource>
                <PMID Version="1">5420325</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84</RefSource>
                <PMID Version="1">22343534</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1983 Nov 10-16;306(5939):194-6</RefSource>
                <PMID Version="1">6646201</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cancer Res Clin Oncol. 1991;117(6):603-7</RefSource>
                <PMID Version="1">1683873</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1997 May 1;57(9):1769-75</RefSource>
                <PMID Version="1">9135021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Mol Pathol. 1999 Jun;66(2):140-8</RefSource>
                <PMID Version="1">10409442</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50</RefSource>
                <PMID Version="1">16199517</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2006 Jun 8;354(23):2419-30</RefSource>
                <PMID Version="1">16760442</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2006 Jun 8;354(23):2431-42</RefSource>
                <PMID Version="1">16760443</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2007 Nov 16;318(5853):1108-13</RefSource>
                <PMID Version="1">17932254</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Biol. 2007;8(11):R232</RefSource>
                <PMID Version="1">17976239</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2008 Mar;26(3):256</RefSource>
                <PMID Version="1">18327223</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 2009 Jan;93(1):17-21</RefSource>
                <PMID Version="1">18692126</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Immunol. 2009 Mar;9(3):175-84</RefSource>
                <PMID Version="1">19240756</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Protoc. 2009;4(7):1073-81</RefSource>
                <PMID Version="1">19561590</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2009 Jul;19(7):1316-23</RefSource>
                <PMID Version="1">19498102</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2009 Sep;6(9):677-81</RefSource>
                <PMID Version="1">19668202</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2009 Sep;19(9):1639-45</RefSource>
                <PMID Version="1">19541911</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2009 Sep 10;461(7261):272-6</RefSource>
                <PMID Version="1">19684571</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Jan 14;463(7278):184-90</RefSource>
                <PMID Version="1">20016488</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Feb;42(2):181-5</RefSource>
                <PMID Version="1">20081860</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Mar 1;26(5):589-95</RefSource>
                <PMID Version="1">20080505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Mar 15;26(6):841-2</RefSource>
                <PMID Version="1">20110278</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2010 Apr;7(4):248-9</RefSource>
                <PMID Version="1">20354512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2010 Apr;38(6):1767-71</RefSource>
                <PMID Version="1">20015970</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2010 Jul 2;329(5987):75-8</RefSource>
                <PMID Version="1">20595611</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2010 Sep;20(9):1297-303</RefSource>
                <PMID Version="1">20644199</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Nov;42(11):969-72</RefSource>
                <PMID Version="1">20890277</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2010 Dec 2;116(23):e118-27</RefSource>
                <PMID Version="1">20733160</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2011 Jan;29(1):24-6</RefSource>
                <PMID Version="1">21221095</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2011 Feb 3;470(7332):115-9</RefSource>
                <PMID Version="1">21179087</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2001 Jan 1;29(1):308-11</RefSource>
                <PMID Version="1">11125122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6</RefSource>
                <PMID Version="1">12900505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2004 Mar;4(3):177-83</RefSource>
                <PMID Version="1">14993899</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2011 Jul 15;27(14):1998-2000</RefSource>
                <PMID Version="1">21624899</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2011 Aug 18;476(7360):298-303</RefSource>
                <PMID Version="1">21796119</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Sep;43(9):830-7</RefSource>
                <PMID Version="1">21804550</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Haematol. 2011 Nov;155(4):477-86</RefSource>
                <PMID Version="1">21981616</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1983 Feb 25;219(4587):963-7</RefSource>
                <PMID Version="1">6401867</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000642">Ammonia-Lyases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002051">Burkitt Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056404">Chaperonin Containing TCP-1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004265">DNA Helicases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044365">GTP-Binding Protein alpha Subunits, G12-G13</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016259">Genes, myc</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051042">Glutamate Formimidoyltransferase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051796">Inhibitor of Differentiation Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016403">Lymphoma, Large B-Cell, Diffuse</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051096">Proto-Oncogene Proteins c-ret</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014178">Translocation, Genetic</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS451613</OtherID>
        <OtherID Source="NLM">PMC3674561</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2468</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2468</ArticleId>
            <ArticleId IdType="pubmed">23143597</ArticleId>
            <ArticleId IdType="pmc">PMC3674561</ArticleId>
            <ArticleId IdType="mid">NIHMS451613</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23143598</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1375-81</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2453</ELocationID>
            <Abstract>
                <AbstractText>Congenital central hypothyroidism occurs either in isolation or in conjunction with other pituitary hormone deficits. Using exome and candidate gene sequencing, we identified 8 distinct mutations and 2 deletions in IGSF1 in males from 11 unrelated families with central hypothyroidism, testicular enlargement and variably low prolactin concentrations. IGSF1 is a membrane glycoprotein that is highly expressed in the anterior pituitary gland, and the identified mutations impair its trafficking to the cell surface in heterologous cells. Igsf1-deficient male mice show diminished pituitary and serum thyroid-stimulating hormone (TSH) concentrations, reduced pituitary thyrotropin-releasing hormone (TRH) receptor expression, decreased triiodothyronine concentrations and increased body mass. Collectively, our observations delineate a new X-linked disorder in which loss-of-function mutations in IGSF1 cause central hypothyroidism, likely secondary to an associated impairment in pituitary TRH signaling.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bak</LastName>
                    <ForeName>Beata</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schoenmakers</LastName>
                    <ForeName>Nadia</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Trotsenburg</LastName>
                    <ForeName>A S Paul</ForeName>
                    <Initials>AS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oostdijk</LastName>
                    <ForeName>Wilma</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voshol</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cambridge</LastName>
                    <ForeName>Emma</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>White</LastName>
                    <ForeName>Jacqueline K</ForeName>
                    <Initials>JK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>le Tissier</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gharavy</LastName>
                    <ForeName>S Neda Mousavy</ForeName>
                    <Initials>SN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martinez-Barbera</LastName>
                    <ForeName>Juan P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stokvis-Brantsma</LastName>
                    <ForeName>Wilhelmina H</ForeName>
                    <Initials>WH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vulsma</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kempers</LastName>
                    <ForeName>Marlies J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Persani</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campi</LastName>
                    <ForeName>Irene</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonomi</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beck-Peccoz</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Hongdong</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davis</LastName>
                    <ForeName>Timothy M E</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hokken-Koelega</LastName>
                    <ForeName>Anita C S</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Del Blanco</LastName>
                    <ForeName>Daria Gorbenko</ForeName>
                    <Initials>DG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rangasami</LastName>
                    <ForeName>Jayanti J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruivenkamp</LastName>
                    <ForeName>Claudia A L</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laros</LastName>
                    <ForeName>Jeroen F J</ForeName>
                    <Initials>JF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kriek</LastName>
                    <ForeName>Marjolein</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kant</LastName>
                    <ForeName>Sarina G</ForeName>
                    <Initials>SG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bosch</LastName>
                    <ForeName>Cathy A J</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biermasz</LastName>
                    <ForeName>Nienke R</ForeName>
                    <Initials>NR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Appelman-Dijkstra</LastName>
                    <ForeName>Natasha M</ForeName>
                    <Initials>NM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corssmit</LastName>
                    <ForeName>Eleonora P</ForeName>
                    <Initials>EP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hovens</LastName>
                    <ForeName>Guido C J</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pereira</LastName>
                    <ForeName>Alberto M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>den Dunnen</LastName>
                    <ForeName>Johan T</ForeName>
                    <Initials>JT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wade</LastName>
                    <ForeName>Michael G</ForeName>
                    <Initials>MG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Breuning</LastName>
                    <ForeName>Martijn H</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hennekam</LastName>
                    <ForeName>Raoul C</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chatterjee</LastName>
                    <ForeName>Krishna</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dattani</LastName>
                    <ForeName>Mehul T</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wit</LastName>
                    <ForeName>Jan M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernard</LastName>
                    <ForeName>Daniel J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>078432</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>084361</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>086545</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>095564</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>095564</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>DK15700</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U117570590</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>U117570590</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>WT077157/Z/05/Z</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005296">Ferrous Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C112314">IGSF1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018025">Receptors, Thyrotropin-Releasing Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>06LU7C9H1V</RegistryNumber>
                <NameOfSubstance UI="D014284">Triiodothyronine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33269-57-7</RegistryNumber>
                <NameOfSubstance UI="C009711">EX 10-478</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9002-62-4</RegistryNumber>
                <NameOfSubstance UI="D011388">Prolactin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9002-71-5</RegistryNumber>
                <NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cardiol. 2008 Mar 28;125(1):41-8</RefSource>
                <PMID Version="1">17434631</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2008 Feb;93(2):410-9</RefSource>
                <PMID Version="1">18000095</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod. 2009 Jan;24(1):241-9</RefSource>
                <PMID Version="1">18854405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2008 Dec 26;283(52):36369-76</RefSource>
                <PMID Version="1">18981173</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Jul 15;25(14):1754-60</RefSource>
                <PMID Version="1">19451168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Aug 15;25(16):2078-9</RefSource>
                <PMID Version="1">19505943</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Apr 1;26(7):873-81</RefSource>
                <PMID Version="1">20147302</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2010 Sep;20(9):1297-303</RefSource>
                <PMID Version="1">20644199</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11482-7</RefSource>
                <PMID Version="1">21636786</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Horm Res Paediatr. 2011;76(1):56-64</RefSource>
                <PMID Version="1">21464560</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2012 Mar;97(3):E452-9</RefSource>
                <PMID Version="1">22188746</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Endocrinol. 2012 Apr;166(4):631-40</RefSource>
                <PMID Version="1">22267279</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thyroid. 1999 Dec;9(12):1265-71</RefSource>
                <PMID Version="1">10646670</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Res. 2000 Mar;47(3):316-23</RefSource>
                <PMID Version="1">10709729</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2000 Jul;141(7):2600-7</RefSource>
                <PMID Version="1">10875264</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2000 Oct;85(10):3631-5</RefSource>
                <PMID Version="1">11061514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2001 Apr;15(4):654-67</RefSource>
                <PMID Version="1">11266515</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2001 Apr;15(4):668-79</RefSource>
                <PMID Version="1">11266516</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Res. 2001 Oct;50(4):479-86</RefSource>
                <PMID Version="1">11568291</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem Lab Med. 2001 Oct;39(10):973-9</RefSource>
                <PMID Version="1">11758614</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods. 2001 Dec;25(4):402-8</RefSource>
                <PMID Version="1">11846609</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Endocrinol. 2002 Oct 31;196(1-2):79-93</RefSource>
                <PMID Version="1">12385827</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2003 Feb;144(2):720-31</RefSource>
                <PMID Version="1">12538635</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2003 Jul;23(14):4882-91</RefSource>
                <PMID Version="1">12832474</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2003 Dec;88(12):5696-703</RefSource>
                <PMID Version="1">14671155</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2004 Mar;18(3):606-23</RefSource>
                <PMID Version="1">14701940</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7</RefSource>
                <PMID Version="1">15075390</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 1973 Oct;37(4):595-601</RefSource>
                <PMID Version="1">4200495</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pediatr. 1980 May;133(3):259-67</RefSource>
                <PMID Version="1">7389739</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 1994 May;78(5):1034-9</RefSource>
                <PMID Version="1">8175956</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Dis Child. 1995 Jul;73(1):17-24</RefSource>
                <PMID Version="1">7639543</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 1998 Mar 1;48(2):157-62</RefSource>
                <PMID Version="1">9521868</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gene. 1998 Jul 3;214(1-2):1-6</RefSource>
                <PMID Version="1">9729118</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 1999 Mar;140(3):1416-22</RefSource>
                <PMID Version="1">10067870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EMBO J. 1999 Apr 1;18(7):1900-4</RefSource>
                <PMID Version="1">10202153</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Hum Biol. 1999 Jul-Aug;26(4):303-8</RefSource>
                <PMID Version="1">10462152</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Endocrinol Invest. 2006 Jul-Aug;29(7):581-93</RefSource>
                <PMID Version="1">16957405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2007 May;92(5):1715-23</RefSource>
                <PMID Version="1">17299073</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Horm Res. 2008;69(1):53-9</RefSource>
                <PMID Version="1">18059084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biotechniques. 2008 Apr;44(5):619-26</RefSource>
                <PMID Version="1">18474036</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003409">Congenital Hypothyroidism</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005296">Ferrous Compounds</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D040181">Genetic Diseases, X-Linked</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007136">Immunoglobulins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010902">Pituitary Gland</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011388">Prolactin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018025">Receptors, Thyrotropin-Releasing Hormone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013733">Testicular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013737">Testis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000033">anatomy &amp; histology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013972">Thyrotropin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014284">Triiodothyronine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">EMS50111</OtherID>
        <OtherID Source="NLM">PMC3511587</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2453</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2453</ArticleId>
            <ArticleId IdType="pubmed">23143598</ArticleId>
            <ArticleId IdType="pmc">PMC3511587</ArticleId>
            <ArticleId IdType="mid">EMS50111</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
